Developmental and Epileptic Encephalopathy 89

Mendelian MONDO:0030856 Pathograph 16 Show in embeddings browser Epilepsy Neurodevelopmental Disorder

Developmental and epileptic encephalopathy 89 (DEE 89) is an autosomal recessive, early-onset epileptic encephalopathy caused by biallelic loss-of-function variants in GAD1. GAD1 encodes GAD67, one of the two glutamic acid decarboxylase isoforms that convert glutamate to GABA. GAD67 is the constitutively active, cytoplasmic isoform and supplies the large majority of basal CNS GABA, so its loss is not buffered by the intact GAD2/GAD65 isoform - which is what makes a recessive defect in a single biosynthetic enzyme sufficient to abolish inhibitory tone from birth. The clinical picture is therefore an inhibitory-failure epilepsy. Seizures are universal; onset across the reported literature runs from birth to six months, and was within the first month in every evaluable patient of the founding cohort. The semiologies are heterogeneous - epileptic spasms and myoclonic seizures predominate, with tonic-clonic and focal motor seizures also reported - and the EEG shows suppression-burst or hypsarrhythmia. Developmental impairment is severe to profound, and four of the eleven patients of the founding cohort died before four years of age. What distinguishes DEE 89 from most channelopathy DEEs is a second, non-neuronal arm. GAD67-derived GABA also acts as a developmental signal outside the nervous system, and the Gad1-null mouse dies at birth of cleft palate. Human patients reproduce that: cleft palate, omphalocele, joint contractures and talipes equinovarus are part of the syndrome, and the contractures are plausibly a fetal-akinesia consequence of the same GABA deficit. This entry curates the neural and the developmental/structural arms as two branches from one shared GABA-depletion node rather than deriving the malformations from the seizures. The same node also carries a third, seizure-independent edge to the developmental encephalopathy itself: GAD67-derived GABA is required for neuronal development and synaptogenesis in the embryo, which is the "developmental" half of "developmental and epileptic encephalopathy". How much of the impairment is developmental and how much is seizure-driven is not known, and that edge is marked accordingly. Two things are deliberately left unresolved. First, an allelic pattern that is suggestive but not established: in the assembled literature series, patients carrying missense variants had neither cleft palate nor omphalocele, while the neurological phenotype did not differ between missense and truncating variants. That is a small-n observation across published case reports, not a measured residual-activity study, so it is recorded as a discussion rather than curated as a subtype. Second, the therapeutic question: vigabatrin (which blocks GABA catabolism) and the ketogenic diet both aim to raise the residual GABA pool, and one infant treated with the combination from the second month of life had seizure cessation and normal psychomotor development at 7 months - against a background in which every other reported patient with a neonatal burst-suppression EEG had profound delay. A single observation on one side and a treated patient who remained refractory on the other is not enough to establish that early combination therapy alters developmental outcome.

Ask OpenScientist

Ask a research question about Developmental and Epileptic Encephalopathy 89. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
10
Pathophys.
20
Phenotypes
3
Gaps
16
Pathograph
1
Genes
4
Medical Actions
2
Models
6
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0030856 developmental and epileptic encephalopathy 89
skos:exactMatch MONDO
MONDO:0030856 is the DEE 89 concept, xrefed to OMIM:619124 and carrying the RO:0004003 causal-gene relationship to HGNC:4092 (GAD1).
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
DEE 89 is autosomal recessive. Affected individuals carry biallelic loss-of-function GAD1 variants; the founding cohort was drawn from six independent consanguineous families, and subsequent reports have been homozygous or compound heterozygous.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:32282878 SUPPORT Human Clinical
"Here we describe a new syndromic developmental and epileptic encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as presented by 11 patients from six independent consanguineous families."
Establishes biallelic (recessive) GAD1 loss of function as the cause, in consanguineous pedigrees.
PMID:32705143 SUPPORT Human Clinical
"Here we present six affected individuals from six unrelated families, carrying bi-allelic GAD1 variants"
Independent replication of biallelic GAD1 inheritance in six further families.
?

Discussions and Knowledge Gaps

3
Do GAD1 missense variants genuinely spare palatal and ventral wall development, and if so is that because they retain residual decarboxylase activity above a developmental threshold that truncating alleles fall below?
KNOWLEDGE GAP OPEN gap_dee89_missense_sparing_of_malformations
Attached to
pathophysiology#Orofacial and Ventral Wall Malformation pathophysiology#Impaired GABA-Dependent Developmental Signaling
Across the published cases, patients carrying missense variants had neither cleft palate nor omphalocele while their neurological phenotype was indistinguishable from that of truncating-variant patients. A dose threshold that development clears but neuronal inhibition does not would explain the pattern, but no residual-activity measurements exist for the human alleles, and the observation rests on a small number of published case reports rather than a systematic cohort. It is recorded here rather than curated as an allelic subtype for that reason.
Proposed experiments
Residual decarboxylase activity of patient GAD1 missense alleles
exp_dee89_gad1_missense_residual_activity
Express the reported missense alleles alongside truncating alleles and wild type, and measure glutamate decarboxylase activity and GABA production, to test whether the missense alleles retain measurable residual activity.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"the comparison of clinical symptoms between patients with missense and truncating mutations did not show any significant clinical difference, except that patients with missense mutations did not show cleft palates or omphaloceles."
States the allelic observation this gap is about: malformations absent in missense-variant patients, neurological phenotype unchanged.
Can any Gad1-loss animal model inform the neurological arm of DEE 89, given that the mouse null dies of cleft palate before an epilepsy phenotype can emerge and the surviving rat null has a mechanistically different seizure type?
HUMAN MODEL MISMATCH OPEN mismatch_dee89_gad1_null_mouse_neonatal_lethality
Attached to
pathophysiology#Early-Onset Epileptic Seizures pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
The malformation arm of this disorder has an excellent model and the neurological arm effectively has none. Gad1-null mice die on the first day of life from cleft palate with no discernible brain defect, so the epilepsy is inaccessible; Gad1-null rats survive but show absence-type spike-wave discharges from two months of age, a thalamocortical oscillation rather than the neonatal spasms with suppression-burst background that define the human disease - and valproate, which helps control rats, worsens the nulls. The mismatch matters because it is exactly the arm where a preclinical model would be used to test the vigabatrin and ketogenic-diet rationale.
Proposed experiments
Palate-rescued conditional Gad1 mouse with neonatal EEG
exp_dee89_palate_rescued_gad1_mouse_eeg
Generate a Gad1 null with palatal development rescued (for example by tissue-restricted expression), so that homozygotes survive the neonatal period, and record EEG through the neonatal and infantile period to establish whether a suppression-burst and spasm phenotype develops.
Show evidence (2 references)
PMID:32705143 SUPPORT Model Organism
"as Gad1-/- mice die neonatally of severe cleft palate, it has not been possible to determine any potential neurological dysfunction"
States the inaccessibility of the neurological phenotype in the mouse null.
PMID:37830095 SUPPORT Model Organism
"VPA treatment alleviated SWD symptoms in control rats, however, counterintuitively exacerbated the symptoms in Gad1 (-/-) rats."
The rat null's paradoxical drug response illustrates why its pharmacology cannot be transferred to patients.
Does starting vigabatrin plus a ketogenic diet in the first weeks after genetic diagnosis change developmental outcome in DEE 89, or only seizure frequency?
KNOWLEDGE GAP OPEN gap_dee89_early_combination_therapy_and_developmental_outcome
Attached to
pathophysiology#Developmental Encephalopathy pathophysiology#GABA Depletion
One infant started on the combination in the second month of life had seizures stop within two days and normal growth and psychomotor development at 7 months, which is remarkable against a cohort in which every patient with a neonatal burst-suppression EEG had profound delay. But a second patient on the same combination, started later, remained refractory with severe delay, and the commentary authors explicitly caution against generalizing from a single case. Because the disorder is ultra-rare and the window appears to be narrow, the question is unlikely to be settled by a conventional trial and needs a prospective registry with a pre-specified developmental endpoint. There is also a mechanistic objection that any such registry would have to stratify for. Vigabatrin works by blocking GABA catabolism, so it can only spare GABA that is being made; where the variant abolishes GAD67 activity there is little to spare, and the 2023 review argues on that basis that vigabatrin is not a suitable solution for severe-reduction or complete-loss alleles. That makes residual enzyme activity - the same quantity the allelic knowledge gap in this entry asks about - the plausible determinant of who responds, and it is not measured in any reported patient. The same review notes that oral GABA does not cross the blood-brain barrier but that brain-penetrant GABA derivatives might, which is the alternative route if the catabolism-blocking rationale really does fail at low residual activity.
Proposed experiments
Prospective treat-on-diagnosis registry with developmental endpoints
exp_dee89_treat_on_diagnosis_registry
Enrol newly genetically diagnosed infants, record time from diagnosis to start of combination therapy, and follow standardized developmental assessments, so that outcome can be related to treatment latency rather than compared across ad hoc case reports.
Vigabatrin response stratified by residual GAD67 activity
exp_dee89_vigabatrin_response_by_residual_activity
For each reported allele, measure residual glutamate decarboxylase activity and relate it to that patient's vigabatrin response, to test the review's prediction that the drug fails where activity is abolished and works only where some synthesis remains.
Show evidence (3 references)
PMID:33169137 SUPPORT Human Clinical
"The presence of a neonatal burst-suppression pattern on EEG generally has a dire prognosis, and all families reported in our study indeed had a profound developmental delay."
Establishes the baseline against which the single favourable outcome stands out, and hence why the question is open rather than answered.
PMID:37029735 SUPPORT Other
"it seems that prescribing vigabatrin for patients with GAD1 deficiency is not a suitable solution, at least for mutations that result in severe reduction or complete loss of the enzyme function."
The genotype-stratified mechanistic objection that any prospective study would have to account for. Support is PARTIAL because it argues against one arm of the intervention rather than resolving the developmental-outcome question this gap asks. Evidence source is OTHER because this is the paper's reasoning over the literature.
PMID:37029735 SUPPORT Other
"However, the production of GABA derivatives with the ability to cross the blood–brain barrier may be useful for controlling epilepsy in these patients."
Names the alternative therapeutic route the same authors propose if the catabolism-blocking rationale fails - brain-penetrant GABA derivatives, since oral GABA does not cross the blood-brain barrier. Evidence source is OTHER because this is the paper's proposal rather than data.
⚙

Pathophysiology

10
Biallelic GAD1 Loss of Function
Biallelic loss-of-function variants in GAD1 (missense, nonsense, splice-site and deletion alleles distributed across the gene) are the initiating lesion. This node captures the single concept of the genetic lesion.
GAD1 hgnc:4092 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GAD1 (hgnc:4092). hgnc:4092 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
GAD67 Enzyme Deficiency Loss-of-function alleles reduce or abolish the activity of the GAD67 enzyme that GAD1 encodes.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Here we describe a new syndromic developmental and epileptic encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as presented by 11 patients from six independent consanguineous families."
Identifies biallelic GAD1 loss-of-function variants as the causal lesion of the syndrome.
GAD67 Enzyme Deficiency
GAD1 encodes GAD67, the rate-limiting glutamic acid decarboxylase that converts L-glutamate to GABA. Biallelic loss of function leaves the cell without functional GAD67. This node captures the single concept of the enzyme deficiency.
glutamate decarboxylase activity GO:0004351 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased glutamate decarboxylase activity (GO:0004351). GO:0004351 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
GABA Depletion Without GAD67, decarboxylation of glutamate to GABA fails; the paralogous GAD65/GAD2 isoform does not compensate because GAD67 supplies most basal GABA.
Show evidence (2 references)
PMID:32282878 SUPPORT Human Clinical
"GAD1 encodes the glutamate decarboxylase enzyme GAD67"
Establishes that the affected gene product is the GAD67 decarboxylase enzyme.
PMID:37029735 SUPPORT Human Clinical
"GAD67 is the rate-limiting enzyme in GABA synthesis, and its deficiency leads to developmental and epileptic encephalopathy 89 (DEE 89)."
Names GAD67 deficiency as the proximate biochemical defect in DEE 89 and identifies it as rate-limiting for GABA synthesis.
GABA Depletion
GAD67 supplies the large majority of basal GABA in the CNS, so its loss depletes the GABA pool rather than merely trimming it - the intact GAD65 isoform, which is nerve-terminal-localized and demand-activated, does not substitute. This node captures the single concept of reduced GABA availability, and is the branch point at which the neural and the developmental/structural arms of the syndrome separate.
GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
GABA biosynthetic process GO:0009449 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased GABA biosynthetic process (GO:0009449). GO:0009449 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Gad1-null mouse (GAD67 knockout) Mouse recapitulates Direct biochemical measurement of the depletion: cortical GAD activity under 20% and GABA content 7% of wild type in newborn nulls.
Downstream
Excitation-Inhibition Imbalance Loss of the inhibitory neurotransmitter shifts cortical circuits toward net excitation.
Impaired GABA-Dependent Developmental Signaling The same depletion removes GABA's non-neurotransmitter developmental signalling role in palatogenesis and in the generation of fetal movement.
Developmental Encephalopathy GAD67-derived GABA is required for neuronal development and synaptogenesis in the embryo, so the developmental impairment is not only a consequence of the seizures. This is the "developmental" half of "developmental and epileptic encephalopathy" - a route from the same depletion node that bypasses the seizures entirely. It is INDIRECT_UNKNOWN_INTERMEDIATES because no published work separates the contributions: the sources assert a developmental role for GAD1 and a severe developmental phenotype, but nobody has shown which part of the impairment survives seizure control, and the one patient in whom seizures were stopped early is a single case.
Show evidence (2 references)
PMID:32705143 SUPPORT Human Clinical
"Its predominant isoform GAD67, contributes up to ∼90% of base-level GABA in the CNS, and is encoded by the GAD1 gene."
Quantifies GAD67's dominant contribution to basal CNS GABA, which is why the intact GAD2/GAD65 isoform cannot compensate for its loss.
PMID:9177246 SUPPORT Model Organism
"GAD activities and GABA contents were reduced to 20% and 7%, respectively, in the cerebral cortex of the newborn GAD67 -/- mice."
Direct measurement of the depletion in the Gad1-null mouse: cortical GABA falls to 7% of wild type. This is model-organism evidence for the magnitude of the depletion; the human biochemical measurement has not been reported.
Excitation-Inhibition Imbalance
Depletion of the principal inhibitory neurotransmitter shifts the balance between glutamatergic excitation and GABAergic inhibition toward net excitation. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.
GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
gamma-aminobutyric acid signaling pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Neuronal Hyperexcitability and Hypersynchrony Reduced inhibitory tone renders neonatal cortical networks hyperexcitable and prone to synchronous discharge.
Show evidence (1 reference)
PMID:32705143 SUPPORT Human Clinical
"Disruption of GAD1 results in an imbalance of inhibitory and excitatory neurotransmitters"
States the excitation-inhibition imbalance as the direct consequence of GAD1 disruption.
Neuronal Hyperexcitability and Hypersynchrony
Networks with little inhibitory restraint fire excessively and synchronously, producing the paroxysmal discharges and the discontinuous suppression-burst background seen on neonatal EEG. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
action potential GO:0001508 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased action potential (GO:0001508). GO:0001508 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Gad1-null rat Rat partially recapitulates GAD1 loss in the rat produces a hypersynchronous electrographic phenotype, supporting the general link from GABA synthesis failure to network hypersynchrony.
Downstream
Early-Onset Epileptic Seizures Hypersynchronous discharge manifests clinically as seizures from the first weeks of life.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Early EEG showed suppression-burst or pattern of burst attenuation or hypsarrhythmia if only recorded in the post-neonatal period."
The suppression-burst and hypsarrhythmic EEG patterns are the electrophysiological signature of the hypersynchronous, poorly restrained neonatal network.
Early-Onset Epileptic Seizures
Every reported patient has seizures. Onset is within the first month of life in the founding cohort and runs from birth to six months across the assembled literature, and the semiology is heterogeneous - epileptic spasms and myoclonic seizures predominate, with tonic-clonic and focal motor seizures also reported. Seizures are frequently drug-resistant. This node captures the single concept of the clinical seizure endpoint and conforms to the shared epilepsy final common pathway.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Animal models
Gad1-null mouse (GAD67 knockout) Mouse fails to recapitulate The defining human phenotype - neonatal epilepsy - cannot be observed in this model. Homozygotes die within a day of birth from the cleft palate, and their brains show no discernible structural defect, so the model gives no information about the seizure phenotype.
Downstream
Developmental Encephalopathy Early, frequent seizures on a suppression-burst background are associated with profound developmental impairment. Whether the seizures cause the developmental arrest, or both reflect the same underlying inhibitory failure, is not resolved - hence unknown intermediates.
Show evidence (5 references)
PMID:32282878 SUPPORT Human Clinical
"All 10 patients, from whom early disease history was available, presented with seizure onset in the first month of life, mainly consisting of epileptic spasms or myoclonic seizures."
Documents first-month seizure onset and the predominant spasm/myoclonic semiology in the founding cohort.
PMID:37029735 SUPPORT Other
"All of the reported patients manifested seizures."
Establishes that seizures occur in every reported patient. Evidence source is OTHER because this is the paper's literature summary rather than its own case observation.
PMID:37029735 SUPPORT Other
"and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
Names the full range of reported semiologies, which is wider than the spasms and myoclonic seizures of the founding cohort. Evidence source is OTHER because this is the paper's literature summary.
+ 2 more references
Impaired GABA-Dependent Developmental Signaling
GABA derived from GAD67 is not only a neurotransmitter: in the embryo it acts as a developmental signal in the formation of the secondary palate and in the generation of fetal movement. Its loss therefore has consequences outside the nervous system. This node captures the single concept of the non-neuronal developmental signalling deficit.
roof of mouth development GO:0060021 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal roof of mouth development (GO:0060021). GO:0060021 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Orofacial and Ventral Wall Malformation Failure of GABA-dependent palatal shelf fusion produces cleft palate; the steps between GABA signalling and shelf fusion are not established.
Reduced Fetal Movement and Joint Contractures Reduced GABA-dependent fetal movement is the proposed route to congenital contractures and talipes; the causal chain is inferred from the phenotype and GAD67's role in fetal movement rather than measured.
Show evidence (2 references)
PMID:37029735 SUPPORT Other
"In the embryonic stages, GAD67 is the major isoform that plays a pivotal role in neuronal development and synaptogenesis, as well as in the normal development of the palate and fetal movements."
States GAD67's developmental role in palate formation and fetal movement, the two extraneural arms curated here. Evidence source is OTHER because this is the review portion of the paper rather than its own case data.
PMID:9177246 SUPPORT Model Organism
"this is the first demonstration of a role for GAD67-derived GABA in the development of nonneural tissue"
The Gad1-null mouse established that GAD67-derived GABA has a required role in non-neural (palatal) development.
Orofacial and Ventral Wall Malformation
Cleft palate is the characteristic malformation, present in a majority of reported patients, and a minority also have an omphalocele. This is the human counterpart of the lethal cleft palate of the Gad1-null mouse. This node captures the single concept of the congenital structural malformations.
roof of mouth development GO:0060021 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal roof of mouth development (GO:0060021). GO:0060021 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Animal models
Gad1-null mouse (GAD67 knockout) Mouse recapitulates All homozygous nulls have severe cleft palate, the same malformation seen in the majority of human patients. This correspondence is what the human founding cohort explicitly invoked.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout Gad1-/- mouse model."
Documents cleft palate and omphalocele in the founding cohort and their correspondence with the mouse null phenotype.
Reduced Fetal Movement and Joint Contractures
Joint contractures and talipes equinovarus are frequent, and are attributed to reduced fetal movement rather than to a primary skeletal defect. This node captures the single concept of the fetal-akinesia-type musculoskeletal consequence.
skeletal joint UBERON:0000982 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skeletal joint (UBERON:0000982). UBERON:0000982 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Eight patients had joint contractures and/or pes equinovarus."
Documents contractures and pes equinovarus in the majority of the founding cohort.
Developmental Encephalopathy
Developmental impairment is severe to profound in every reported patient bar one, who had moderate intellectual disability and was ambulant; the rest were bed-confined. About a third of the founding cohort died in early childhood. This node captures the single concept of the developmental and mortality endpoint.
Show evidence (3 references)
PMID:37029735 SUPPORT Other
"Patients who suffered from this syndrome generally manifested severe to profound neurodevelopmental delay, seizures, and often congenital anomalies such as the cleft palate or/and omphalocele."
Summarizes the severe-to-profound developmental phenotype across the published cases. Evidence source is OTHER because this statement summarizes the literature rather than the paper's own single case.
PMID:32282878 SUPPORT Human Clinical
"Four patients died before 4 years of age."
Documents early childhood mortality in four of the eleven patients of the founding cohort.
PMID:37029735 SUPPORT Other
"Literature review revealed all reported patients, except for one patient who had moderate ID and ambulation, suffered from severe to profound ID and were bed‐confined."
Supports the severity and functional-status half of this node's claim - all but one reported patient severely-to-profoundly impaired and bed-confined. Evidence source is OTHER because this is the paper's literature summary.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Developmental and Epileptic Encephalopathy 89 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

20
Head and Neck 1
Cleft Palate HP:0000175 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cleft palate (HP:0000175). HP:0000175 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout Gad1-/- mouse model."
Documents cleft palate in seven of eleven patients.
Limbs 1
Talipes Equinovarus HP:0001762 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Talipes equinovarus (HP:0001762). HP:0001762 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Eight patients had joint contractures and/or pes equinovarus."
Documents pes equinovarus in the founding cohort.
Musculoskeletal 3
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"The clinical investigation has shown that spasms and hypotonia are common among reported patients."
States that hypotonia is common across reported patients. Evidence source is OTHER because this is a literature summary.
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"he manifested severe neurodevelopmental delay with bed confinement, spasticity in limbs, speech absence, and incontinency."
Documents limb spasticity in the index patient. No frequency band is asserted because this is a single-patient observation.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"Common dysmorphological symptoms in these patients included scoliosis, cleft palate, omphalocele, club foot, plagiocephaly, and arthrogryposis."
Lists scoliosis among the recurrent dysmorphic findings. Evidence source is OTHER because this is the paper's literature summary.
Nervous System 9
Seizures OBLIGATE HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"All of the reported patients manifested seizures."
A literature review across all published cases reports seizures in every patient, which is what carries the OBLIGATE band. Evidence source is OTHER because this is the paper's literature summary rather than its own case.
Epileptic Spasms HP:0011097 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epileptic spasm (HP:0011097). HP:0011097 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"mainly consisting of epileptic spasms or myoclonic seizures"
Names epileptic spasms as a predominant early semiology.
Bilateral Tonic-Clonic Seizures HP:0002069 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral tonic-clonic seizure (HP:0002069). HP:0002069 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
Names tonic-clonic seizures among the reported semiologies. Evidence source is OTHER because this is the paper's literature summary.
Suppression-Burst EEG EEG with burst suppression HP:0010851 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is EEG with burst suppression (HP:0010851). HP:0010851 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Early EEG showed suppression-burst or pattern of burst attenuation or hypsarrhythmia if only recorded in the post-neonatal period."
Documents the suppression-burst / burst-attenuation neonatal EEG.
Hypsarrhythmia HP:0002521 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypsarrhythmia (HP:0002521). HP:0002521 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Early EEG showed suppression-burst or pattern of burst attenuation or hypsarrhythmia if only recorded in the post-neonatal period."
Documents hypsarrhythmia on post-neonatal recordings.
Severe to Profound Developmental Delay Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"Patients who suffered from this syndrome generally manifested severe to profound neurodevelopmental delay, seizures, and often congenital anomalies such as the cleft palate or/and omphalocele."
Summarizes severe-to-profound neurodevelopmental delay across published cases. Evidence source is OTHER because this is the paper's literature summary rather than its own case observation.
Absent Speech HP:0001344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent speech (HP:0001344). HP:0001344 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"he manifested severe neurodevelopmental delay with bed confinement, spasticity in limbs, speech absence, and incontinency."
Documents absent speech in the index patient. No frequency band is asserted because this is a single-patient observation.
Cerebral Atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral atrophy (HP:0002059). HP:0002059 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"MRI showed diffuse cerebral atrophy and severe ventriculomegaly."
Documents cerebral atrophy on MRI in the index patient. No frequency band is asserted because the same paper reports MRI as normal in the majority.
Ventriculomegaly HP:0002119 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ventriculomegaly (HP:0002119). HP:0002119 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"MRI showed diffuse cerebral atrophy and severe ventriculomegaly."
Documents ventriculomegaly on MRI in the index patient. No frequency band is asserted because this is a single-patient observation.
Other 6
Neonatal-Onset Seizures FREQUENT Neonatal seizure HP:0032807 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32282878 SUPPORT Human Clinical
"All 10 patients, from whom early disease history was available, presented with seizure onset in the first month of life, mainly consisting of epileptic spasms or myoclonic seizures."
Ten patients with first-month onset, against a total published literature of roughly nineteen, gives a derived lower bound above 50% - the FREQUENT band (30-79%). A higher band is not asserted because the review below reports onset extending to six months.
PMID:37029735 SUPPORT Other
"In reported patients, the age‐onset of seizures was from the birth to 6 months old"
Support is PARTIAL because this sentence bounds the claim rather than making it: onset across the published literature runs from birth to six months, so neonatal onset is characteristic but not universal, which is why the band is FREQUENT rather than higher. Evidence source is OTHER because this is the paper's literature summary. The quote carries a U+2010 hyphen in "age-onset" and a U+2009 thin space before "months", copied verbatim from the source.
Myoclonic Seizures HP:0032794 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonic seizure (HP:0032794). HP:0032794 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"mainly consisting of epileptic spasms or myoclonic seizures"
Names myoclonic seizures as a predominant early semiology.
Focal Motor Seizures HP:0011153 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Focal motor seizure (HP:0011153). HP:0011153 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
Names focal motor seizures among the reported semiologies. Evidence source is OTHER because this is the paper's literature summary.
Omphalocele HP:0001539 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Omphalocele (HP:0001539). HP:0001539 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout Gad1-/- mouse model."
Documents omphalocele in two of eleven patients.
Congenital Joint Contractures Congenital contracture HP:0002803 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital contracture (HP:0002803). HP:0002803 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Eight patients had joint contractures and/or pes equinovarus."
Documents joint contractures in eight of eleven patients.
Plagiocephaly HP:0001357 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Plagiocephaly (HP:0001357). HP:0001357 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"Common dysmorphological symptoms in these patients included scoliosis, cleft palate, omphalocele, club foot, plagiocephaly, and arthrogryposis."
Lists plagiocephaly among the recurrent dysmorphic findings. Evidence source is OTHER because this is the paper's literature summary.
🧬

Genetic Associations

1
GAD1
Gene: GAD1 hgnc:4092 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GAD1 (hgnc:4092). hgnc:4092 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:37029735 SUPPORT Human Clinical
"The recurrent c.1591C>T, p.(Arg531*) variant has been reported three times (20% of all reported variants) in different populations, indicating it may be a probable hotspot mutation."
Documents the recurrent p.(Arg531*) nonsense allele and its share of reported variants.
PMID:37029735 SUPPORT Computational
"The mutation is located in the PLP‐binding domain, which is important for the activity of the protein"
Locates a reported missense allele in the pyridoxal-phosphate-binding domain, the structural basis on which missense alleles are argued to impair catalysis. Evidence source is COMPUTATIONAL because the functional inference rests on docking and molecular-dynamics simulation, not an enzyme assay.
💊

Medical Actions

4
Vigabatrin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: vigabatrin CHEBI:63638 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vigabatrin (CHEBI:63638). CHEBI:63638 is a therapeutic agent from Chemical Entities of Biological Interest.
Vigabatrin irreversibly inhibits GABA transaminase, the enzyme that degrades GABA, and is therefore a mechanistically rational attempt to raise whatever GABA the residual synthetic capacity produces. Five of seven patients in the founding cohort who tried it had a good seizure response, but the authors themselves cautioned that the responders were particularly those with epileptic spasms, so the effect may be semiology-driven rather than GAD1-specific. The rationale has a published objection, and it is a mechanistic one rather than a null trial result: sparing GABA from degradation cannot help much when synthesis is the step that has failed, since GAD67 supplies over 90% of basal GABA. The 2023 review states that vigabatrin is therefore not a suitable solution "at least for mutations that result in severe reduction or complete loss of the enzyme function" - a genotype-stratified claim, which is the same residual-activity axis this entry records as an open gap. Two treated patients, including one on the vigabatrin-plus-ketogenic-diet combination, continued to have seizures. Both sides are curated as evidence below rather than resolved here, because the objection is an inference from the mechanism and the response is an observation, and neither refutes the other.
Mechanism Target:
RESTORES GABA Depletion — Blocking GABA catabolism is intended to raise the available GABA pool and partially offset the synthetic deficit. The link is mechanistic rationale plus an observed clinical seizure response, not a measured rise in human brain GABA.
Show evidence (2 references)
PMID:33169137 SUPPORT Other
"Both treatment strategies are thought to increase the available pool of GABA, and combined they might compensate for the severely impaired GABA synthesis."
States the intended mechanism - raising the available GABA pool to compensate for impaired synthesis - for vigabatrin and the ketogenic diet.
PMID:37029735 REFUTE Other
"it seems that prescribing vigabatrin for patients with GAD1 deficiency is not a suitable solution, at least for mutations that result in severe reduction or complete loss of the enzyme function."
The direct argument against this link. Because GAD67 supplies most basal GABA, blocking catabolism has little left to spare where the variant abolishes synthesis, so the restorative effect is expected to fail for null and severe-reduction alleles. `treatment_effect` remains RESTORES because that is the intended mechanism the drug is chosen for; this item records that the intent is disputed on mechanistic grounds. Evidence source is OTHER because this is the paper's reasoning over the literature rather than a measurement.
Show evidence (2 references)
PMID:33169137 SUPPORT Human Clinical
"In our report, five of seven patients who tried vigabatrin showed a remarkably good seizure response."
Reports the vigabatrin response rate in the founding cohort. Support is PARTIAL because the same authors attribute the response partly to seizure type (epileptic spasms) rather than to the GAD1 genotype.
PMID:37029735 REFUTE Other
"regardless of the taking of the combination of vigabatrin and ketogenic diet, continued to suffer from epilepsy."
The clinical counterweight to that response rate: the 2023 index patient and a patient from the independent series both continued to have seizures on the vigabatrin-plus-ketogenic-diet combination. Evidence source is OTHER because this is the paper's summary of published cases alongside its own.
Ketogenic Diet
Action: Ketogenic DietNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Ketogenic Diet (NCIT:C173168). NCIT:C173168 is a clinical intervention from the NCI Thesaurus. NCIT:C173168
The ketogenic diet is used alongside vigabatrin on the same rationale of increasing the available GABA pool. Its disease-specific evidence is a single treated infant with an excellent outcome set against at least two patients on the same combination who remained refractory.
Mechanism Target:
RESTORES GABA Depletion — The diet is proposed to increase the available GABA pool; this is a hypothesized mechanism carried over from ketogenic-diet pharmacology generally, not a measurement made in GAD1-deficient patients.
Show evidence (1 reference)
PMID:33169137 SUPPORT Other
"Both treatment strategies are thought to increase the available pool of GABA, and combined they might compensate for the severely impaired GABA synthesis."
States the intended GABA-raising mechanism shared by the ketogenic diet and vigabatrin.
Show evidence (1 reference)
PMID:33169137 SUPPORT Human Clinical
"One patient (Patient C) also appears to take a combination of ketogenic diet and vigabatrin at the age of 28 months, and still has refractory seizures and severe delay."
Records a treated patient who remained refractory on the same combination. Support is PARTIAL because the disease-specific evidence for the diet points in both directions.
Early Combined Vigabatrin and Ketogenic Diet
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: vigabatrin CHEBI:63638 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vigabatrin (CHEBI:63638). CHEBI:63638 is a therapeutic agent from Chemical Entities of Biological Interest.
Combination therapy started in the second month of life, immediately after genetic diagnosis, was reported in one infant to stop seizures within two days and leave growth and psychomotor development unremarkable at 7 months - a striking exception in a disorder where a neonatal burst-suppression EEG has otherwise predicted profound delay. It is one observation, and another patient on the same combination started later remained refractory.
Mechanism Target:
RESTORES GABA Depletion — Both components are proposed to raise the available GABA pool - vigabatrin by blocking GABA catabolism, the ketogenic diet by shifting substrate availability - so the combination is directed at the same depletion node each single agent targets. The effect is an inferred mechanism, not a measured rise in human brain GABA.
Show evidence (1 reference)
PMID:33169137 SUPPORT Other
"Both treatment strategies are thought to increase the available pool of GABA, and combined they might compensate for the severely impaired GABA synthesis."
The authors' stated rationale for combining the two agents, directed at the GABA pool. Graded OTHER because it is mechanistic reasoning rather than a patient observation, and PARTIAL because no measurement of GABA in treated patients is reported.
Show evidence (2 references)
PMID:33169137 SUPPORT Human Clinical
"This combination treatment not only resulted in clinical cessation of seizures within 2 days, but at 7 months of age, growth and psychomotor development were unremarkable."
Reports the single favourable outcome on early combination therapy. Support is PARTIAL because the same commentary explicitly cautions against drawing conclusions from one observation.
PMID:33169137 SUPPORT Other
"While this is certainly a reasonable hypothesis, one should be cautious drawing conclusions from one single observation."
The authors' own caution about the strength of the single-patient developmental-outcome claim.
Individualized Antiseizure Medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
No single antiseizure medication has emerged as the treatment of choice. Across the patients whose epilepsy was controlled there was no drug in common, so regimen choice remains empirical.
Show evidence (1 reference)
PMID:37029735 SUPPORT Human Clinical
"we found that there was no common drug therapy among patients whose epilepsy was controlled"
Documents the absence of a shared effective drug across controlled cases, supporting individualized rather than protocolized therapy.
🔬

Diagnosis

2
Molecular Genetic Testing
The diagnosis rests on identification of biallelic pathogenic GAD1 variants, typically by exome sequencing, in an infant with neonatal-onset epileptic encephalopathy. There is no specific biochemical marker in routine use; metabolic screening was normal in the reported case where it was performed.
Show evidence (1 reference)
PMID:32705143 SUPPORT Human Clinical
"Our findings highlight an important role for GAD1 in seizure induction, neuronal and extraneuronal development, and introduce GAD1 as a new gene associated with developmental and epileptic encephalopathy."
Establishes GAD1 as the gene to be tested in this presentation; the diagnosis is molecular.
Neuroimaging
Brain MRI is normal in most patients early on; later imaging at older ages can show atrophic change, so a normal early MRI does not argue against the diagnosis.
Show evidence (1 reference)
PMID:37029735 SUPPORT Other
"The majority of the patients had normal MRI, although, in some patients, later MRI at older ages revealed defects."
Records that MRI is usually normal initially with later abnormalities in some. Evidence source is OTHER because this is the paper's literature summary.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Fewer than twenty patients have been reported since the syndrome was defined in 2020: eleven in the founding cohort, six in an independent series, and isolated further cases. No population rate has been estimated, and no frequency band is asserted here.
Show evidence (2 references)
PMID:32282878 SUPPORT Human Clinical
"Here we describe a new syndromic developmental and epileptic encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as presented by 11 patients from six independent consanguineous families."
Provides the founding literature case count; no normalized population rate is asserted.
PMID:32705143 SUPPORT Human Clinical
"Here we present six affected individuals from six unrelated families, carrying bi-allelic GAD1 variants"
Adds six further reported patients to the literature count.
🐁

Animal Models

2
Gad1-null mouse (GAD67 knockout)
Targeted disruption of exon 1 of mouse Gad1 abolishes GAD67. Homozygotes are born at Mendelian frequency but die on the first morning after birth with severe cleft palate, and cortical GABA is reduced to 7% of wild type. Because death is neonatal, the model cannot be used to study the epilepsy that defines the human disorder.
Species
Mouse
Genotype
Gad1 (GAD67) homozygous null
Publication
PMID:9177246
Pathograph links
GABA Depletion recapitulates fidelity: high Direct biochemical measurement of the depletion: cortical GAD activity under 20% and GABA content 7% of wild type in newborn nulls.
Limitations: Measured in newborn mouse cerebral cortex; the equivalent measurement has not been made in human patients, so the magnitude is transferred by inference.
Readouts
Cerebral cortical GABA content
HPLC measurement of GABA in cerebral cortex homogenate of P0.5 nulls against wild-type littermates.
Direction: DECREASED
Interpretation: GABA at 7% of wild type is the quantitative correlate of the depletion node.
Show evidence (1 reference)
PMID:9177246 SUPPORT Model Organism
"GAD activities and GABA contents were reduced to 20% and 7%, respectively, in the cerebral cortex of the newborn GAD67 -/- mice."
Reports the cortical GAD activity and GABA measurements.
Show evidence (1 reference)
PMID:9177246 SUPPORT Model Organism
"GAD activities and GABA contents were reduced to 20% and 7%, respectively, in the cerebral cortex of the newborn GAD67 -/- mice."
Supports treating the null mouse as informative for the GABA-depletion node.
Orofacial and Ventral Wall Malformation recapitulates fidelity: high All homozygous nulls have severe cleft palate, the same malformation seen in the majority of human patients. This correspondence is what the human founding cohort explicitly invoked.
Limitations: The mouse cleft palate is fully penetrant and lethal, whereas human cleft palate is present in a majority but not all patients and is survivable; and the mouse shows no omphalocele counterpart.
Readouts
Secondary palate fusion
Gross and histological examination of the upper jaw and coronal facial sections in newborn and E17.5 animals.
Direction: ABOLISHED
Interpretation: Complete failure of secondary palate formation in every homozygote is the structural readout for this node.
Show evidence (1 reference)
PMID:9177246 SUPPORT Model Organism
"Severe cleft palate was found in all homozygous mutants"
Reports full penetrance of the cleft palate readout.
Show evidence (1 reference)
PMID:32282878 SUPPORT Human Clinical
"Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout Gad1-/- mouse model."
The human study itself identifies the mouse null as reproducing the patients' malformation phenotype, which is what makes the model informative for this node.
Early-Onset Epileptic Seizures fails to recapitulate fidelity: low The defining human phenotype - neonatal epilepsy - cannot be observed in this model. Homozygotes die within a day of birth from the cleft palate, and their brains show no discernible structural defect, so the model gives no information about the seizure phenotype.
Limitations: This is a negative result by inaccessibility rather than by measurement: the animals do not survive long enough for an epilepsy phenotype to develop or be recorded, and no EEG was obtained. It should not be read as evidence that GAD67 loss fails to cause seizures.
Show evidence (2 references)
PMID:32705143 SUPPORT Model Organism
"as Gad1-/- mice die neonatally of severe cleft palate, it has not been possible to determine any potential neurological dysfunction"
States explicitly that neonatal lethality prevents the mouse from informing the neurological phenotype.
+ 1 more reference
Show evidence (1 reference)
PMID:9177246 SUPPORT Model Organism
"These mice were born at the expected frequency but died of severe cleft palate during the first morning after birth."
Establishes the model and its neonatal lethal cleft-palate phenotype, which is what makes it informative for the malformation arm and uninformative for the epilepsy arm.
Gad1-null rat
Unlike the mouse, Gad1-null rats survive to adulthood and can be recorded by chronic EEG. They show abundant spike-wave discharges from two months of age and reduced GABA immunoreactivity in reticular thalamic neuronal somata. The seizure phenotype is absence-type spike-wave discharge, not the neonatal spasms and suppression-burst pattern of the human disorder.
Species
Rat
Genotype
Gad1 homozygous knockout
Publication
PMID:37830095
Pathograph links
Neuronal Hyperexcitability and Hypersynchrony partially recapitulates fidelity: low GAD1 loss in the rat produces a hypersynchronous electrographic phenotype, supporting the general link from GABA synthesis failure to network hypersynchrony.
Limitations: The discharge type is absence-like spike-wave activity in adolescent and adult animals, mechanistically a thalamocortical oscillation, rather than the neonatal epileptic spasms and suppression-burst background that define the human disease. Common laboratory rat strains also show spike-wave discharges spontaneously, so the phenotype is a shift in severity against a noisy background rather than an all-or-none disease model. Valproate, which suppressed discharges in controls, made them worse in the nulls, so drug responses in this model should not be transferred to patients.
Readouts
Reticular thalamic somatic GABA immunoreactivity
Immunohistochemistry for GABA in reticular thalamic nucleus neurons of null versus control rats.
Direction: DECREASED
Interpretation: Confirms that the electrographic phenotype is accompanied by the expected loss of GABA in the implicated inhibitory nucleus.
Show evidence (1 reference)
PMID:37830095 SUPPORT Model Organism
"GABA immunoreactivity was significantly reduced in the somata of RTN neurons in Gad1 (-/-) rats but not in their axons targeting the thalamus."
Reports the immunohistochemical GABA measurement.
Show evidence (1 reference)
PMID:37830095 SUPPORT Model Organism
"VPA treatment alleviated SWD symptoms in control rats, however, counterintuitively exacerbated the symptoms in Gad1 (-/-) rats."
The paradoxical valproate response is why this model is treated as only partially informative and its pharmacology is not transferred to patients.
Show evidence (1 reference)
PMID:37830095 SUPPORT Model Organism
"SWDs were abundant in EEG from Gad1 (-/-) rats as young as 2 months old."
Establishes that this model, unlike the mouse, survives to yield an electrographic seizure phenotype.
{ }

Source YAML

click to show 
name: Developmental and Epileptic Encephalopathy 89
creation_date: "2026-08-27T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: developmental and epileptic encephalopathy 89
  term:
    id: MONDO:0030856
    label: developmental and epileptic encephalopathy 89
synonyms:
- DEE89
- DEE 89
- GAD1 deficiency
- GAD67 deficiency
description: >-
  Developmental and epileptic encephalopathy 89 (DEE 89) is an autosomal
  recessive, early-onset epileptic encephalopathy caused by biallelic
  loss-of-function variants in GAD1. GAD1 encodes GAD67, one of the two glutamic
  acid decarboxylase isoforms that convert glutamate to GABA. GAD67 is the
  constitutively active, cytoplasmic isoform and supplies the large majority of
  basal CNS GABA, so its loss is not buffered by the intact GAD2/GAD65 isoform -
  which is what makes a recessive defect in a single biosynthetic enzyme
  sufficient to abolish inhibitory tone from birth.

  The clinical picture is therefore an inhibitory-failure epilepsy. Seizures are
  universal; onset across the reported literature runs from birth to six months,
  and was within the first month in every evaluable patient of the founding
  cohort. The semiologies are heterogeneous - epileptic spasms and myoclonic
  seizures predominate, with tonic-clonic and focal motor seizures also reported -
  and the EEG shows suppression-burst or hypsarrhythmia. Developmental impairment
  is severe to profound, and four of the eleven patients of the founding cohort
  died before four years of age.

  What distinguishes DEE 89 from most channelopathy DEEs is a second,
  non-neuronal arm. GAD67-derived GABA also acts as a developmental signal
  outside the nervous system, and the Gad1-null mouse dies at birth of cleft
  palate. Human patients reproduce that: cleft palate, omphalocele, joint
  contractures and talipes equinovarus are part of the syndrome, and the
  contractures are plausibly a fetal-akinesia consequence of the same GABA
  deficit. This entry curates the neural and the developmental/structural arms
  as two branches from one shared GABA-depletion node rather than deriving the
  malformations from the seizures. The same node also carries a third,
  seizure-independent edge to the developmental encephalopathy itself: GAD67-derived
  GABA is required for neuronal development and synaptogenesis in the embryo, which
  is the "developmental" half of "developmental and epileptic encephalopathy". How
  much of the impairment is developmental and how much is seizure-driven is not
  known, and that edge is marked accordingly.

  Two things are deliberately left unresolved. First, an allelic pattern that is
  suggestive but not established: in the assembled literature series, patients
  carrying missense variants had neither cleft palate nor omphalocele, while the
  neurological phenotype did not differ between missense and truncating
  variants. That is a small-n observation across published case reports, not a
  measured residual-activity study, so it is recorded as a discussion rather
  than curated as a subtype. Second, the therapeutic question: vigabatrin (which
  blocks GABA catabolism) and the ketogenic diet both aim to raise the residual
  GABA pool, and one infant treated with the combination from the second month
  of life had seizure cessation and normal psychomotor development at 7 months -
  against a background in which every other reported patient with a neonatal
  burst-suppression EEG had profound delay. A single observation on one side and
  a treated patient who remained refractory on the other is not enough to
  establish that early combination therapy alters developmental outcome.
parents:
- Epilepsy
- Neurodevelopmental Disorder
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0030856
      label: developmental and epileptic encephalopathy 89
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0030856 is the DEE 89 concept, xrefed to OMIM:619124 and carrying the
      RO:0004003 causal-gene relationship to HGNC:4092 (GAD1).
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    DEE 89 is autosomal recessive. Affected individuals carry biallelic
    loss-of-function GAD1 variants; the founding cohort was drawn from six
    independent consanguineous families, and subsequent reports have been
    homozygous or compound heterozygous.
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we describe a new syndromic developmental and epileptic
      encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as
      presented by 11 patients from six independent consanguineous families.
    explanation: >-
      Establishes biallelic (recessive) GAD1 loss of function as the cause, in
      consanguineous pedigrees.
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we present six affected individuals from six unrelated families,
      carrying bi-allelic GAD1 variants
    explanation: >-
      Independent replication of biallelic GAD1 inheritance in six further
      families.
pathophysiology:
- name: Biallelic GAD1 Loss of Function
  description: >-
    Biallelic loss-of-function variants in GAD1 (missense, nonsense, splice-site
    and deletion alleles distributed across the gene) are the initiating lesion.
    This node captures the single concept of the genetic lesion.
  role: trigger
  biological_scale: MOLECULAR
  gene:
    preferred_term: GAD1
    term:
      id: hgnc:4092
      label: GAD1
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we describe a new syndromic developmental and epileptic
      encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as
      presented by 11 patients from six independent consanguineous families.
    explanation: >-
      Identifies biallelic GAD1 loss-of-function variants as the causal lesion of
      the syndrome.
  downstream:
  - target: GAD67 Enzyme Deficiency
    causal_link_type: DIRECT
    description: >-
      Loss-of-function alleles reduce or abolish the activity of the GAD67
      enzyme that GAD1 encodes.
- name: GAD67 Enzyme Deficiency
  description: >-
    GAD1 encodes GAD67, the rate-limiting glutamic acid decarboxylase that
    converts L-glutamate to GABA. Biallelic loss of function leaves the cell
    without functional GAD67. This node captures the single concept of the enzyme
    deficiency.
  role: mediator
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: glutamate decarboxylase activity
    term:
      id: GO:0004351
      label: glutamate decarboxylase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GAD1 encodes the glutamate decarboxylase enzyme GAD67
    explanation: >-
      Establishes that the affected gene product is the GAD67 decarboxylase
      enzyme.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GAD67 is the rate-limiting enzyme in GABA synthesis, and its deficiency
      leads to developmental and epileptic encephalopathy 89 (DEE 89).
    explanation: >-
      Names GAD67 deficiency as the proximate biochemical defect in DEE 89 and
      identifies it as rate-limiting for GABA synthesis.
  downstream:
  - target: GABA Depletion
    causal_link_type: DIRECT
    description: >-
      Without GAD67, decarboxylation of glutamate to GABA fails; the paralogous
      GAD65/GAD2 isoform does not compensate because GAD67 supplies most basal
      GABA.
- name: GABA Depletion
  description: >-
    GAD67 supplies the large majority of basal GABA in the CNS, so its loss
    depletes the GABA pool rather than merely trimming it - the intact GAD65
    isoform, which is nerve-terminal-localized and demand-activated, does not
    substitute. This node captures the single concept of reduced GABA
    availability, and is the branch point at which the neural and the
    developmental/structural arms of the syndrome separate.
  role: mediator
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA biosynthetic process
    term:
      id: GO:0009449
      label: GABA biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its predominant isoform GAD67, contributes up to ∼90% of base-level GABA
      in the CNS, and is encoded by the GAD1 gene.
    explanation: >-
      Quantifies GAD67's dominant contribution to basal CNS GABA, which is why
      the intact GAD2/GAD65 isoform cannot compensate for its loss.
  - reference: PMID:9177246
    reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GAD activities and GABA contents were reduced to 20% and 7%,
      respectively, in the cerebral cortex of the newborn GAD67 -/- mice.
    explanation: >-
      Direct measurement of the depletion in the Gad1-null mouse: cortical GABA
      falls to 7% of wild type. This is model-organism evidence for the
      magnitude of the depletion; the human biochemical measurement has not been
      reported.
  downstream:
  - target: Excitation-Inhibition Imbalance
    causal_link_type: DIRECT
    description: >-
      Loss of the inhibitory neurotransmitter shifts cortical circuits toward net
      excitation.
  - target: Impaired GABA-Dependent Developmental Signaling
    causal_link_type: DIRECT
    description: >-
      The same depletion removes GABA's non-neurotransmitter developmental
      signalling role in palatogenesis and in the generation of fetal movement.
  - target: Developmental Encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      GAD67-derived GABA is required for neuronal development and synaptogenesis in
      the embryo, so the developmental impairment is not only a consequence of the
      seizures. This is the "developmental" half of "developmental and epileptic
      encephalopathy" - a route from the same depletion node that bypasses the
      seizures entirely. It is INDIRECT_UNKNOWN_INTERMEDIATES because no published
      work separates the contributions: the sources assert a developmental role for
      GAD1 and a severe developmental phenotype, but nobody has shown which part of
      the impairment survives seizure control, and the one patient in whom seizures
      were stopped early is a single case.
    evidence:
    - reference: PMID:32705143
      reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Our findings highlight an important role for GAD1 in seizure induction,
        neuronal and extraneuronal development, and introduce GAD1 as a new gene
        associated with developmental and epileptic encephalopathy.
      explanation: >-
        Names seizure induction and neuronal development as separate roles of GAD1,
        which is the basis for a developmental route that does not run through the
        seizures.
    - reference: PMID:37029735
      reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In the embryonic stages, GAD67 is the major isoform that plays a pivotal
        role in neuronal development and synaptogenesis, as well as in the normal
        development of the palate and fetal movements.
      explanation: >-
        The neuronal-development-and-synaptogenesis clause of this sentence is what
        this edge carries; the palate and fetal-movement clauses are carried by the
        extraneural node. Evidence source is OTHER because this is the paper's
        literature summary.
- name: Excitation-Inhibition Imbalance
  description: >-
    Depletion of the principal inhibitory neurotransmitter shifts the balance
    between glutamatergic excitation and GABAergic inhibition toward net
    excitation. This node captures the single concept of the excitation-inhibition
    imbalance and conforms to the shared epilepsy final common pathway.
  role: mediator
  biological_scale: CELLULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Disruption of GAD1 results in an imbalance of inhibitory and excitatory
      neurotransmitters
    explanation: >-
      States the excitation-inhibition imbalance as the direct consequence of
      GAD1 disruption.
  downstream:
  - target: Neuronal Hyperexcitability and Hypersynchrony
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced inhibitory tone renders neonatal cortical networks hyperexcitable
      and prone to synchronous discharge.
- name: Neuronal Hyperexcitability and Hypersynchrony
  description: >-
    Networks with little inhibitory restraint fire excessively and synchronously,
    producing the paroxysmal discharges and the discontinuous suppression-burst
    background seen on neonatal EEG. This node captures the single concept of
    network hyperexcitability and conforms to the shared epilepsy final common
    pathway.
  role: central_effector
  biological_scale: CELLULAR
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: action potential
    term:
      id: GO:0001508
      label: action potential
    modifier: INCREASED
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early EEG showed suppression-burst or pattern of burst attenuation or
      hypsarrhythmia if only recorded in the post-neonatal period.
    explanation: >-
      The suppression-burst and hypsarrhythmic EEG patterns are the
      electrophysiological signature of the hypersynchronous, poorly restrained
      neonatal network.
  downstream:
  - target: Early-Onset Epileptic Seizures
    causal_link_type: DIRECT
    description: >-
      Hypersynchronous discharge manifests clinically as seizures from the first
      weeks of life.
- name: Early-Onset Epileptic Seizures
  description: >-
    Every reported patient has seizures. Onset is within the first month of life
    in the founding cohort and runs from birth to six months across the assembled
    literature, and the semiology is heterogeneous - epileptic spasms and
    myoclonic seizures predominate, with tonic-clonic and focal motor seizures
    also reported. Seizures are frequently drug-resistant. This node captures the
    single concept of the clinical seizure endpoint and conforms to the shared
    epilepsy final common pathway.
  role: effector
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 10 patients, from whom early disease history was available, presented
      with seizure onset in the first month of life, mainly consisting of
      epileptic spasms or myoclonic seizures.
    explanation: >-
      Documents first-month seizure onset and the predominant spasm/myoclonic
      semiology in the founding cohort.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "All of the reported patients manifested seizures."
    explanation: >-
      Establishes that seizures occur in every reported patient. Evidence source
      is OTHER because this is the paper's literature summary rather than its own
      case observation.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
    explanation: >-
      Names the full range of reported semiologies, which is wider than the spasms
      and myoclonic seizures of the founding cohort. Evidence source is OTHER
      because this is the paper's literature summary.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In reported patients, the age‐onset of seizures was from the birth to 6 months old"
    explanation: >-
      States the onset window this node's description asserts - birth to six
      months across the published literature, wider than the first-month onset of
      the founding cohort. Evidence source is OTHER because this is the paper's
      literature summary.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, the administration of antiseizure medications led to the control of epilepsy, but in others, epilepsy remained uncontrolled."
    explanation: >-
      Backs the drug-resistance claim in this node's description: some patients are
      controlled on antiseizure medication and others are not. HPO has no term for
      drug-resistant epilepsy reachable through the configured adapter, so
      refractoriness is recorded here rather than bound as a phenotype. Evidence
      source is OTHER because this is the paper's literature summary.
  downstream:
  - target: Developmental Encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Early, frequent seizures on a suppression-burst background are associated
      with profound developmental impairment. Whether the seizures cause the
      developmental arrest, or both reflect the same underlying inhibitory
      failure, is not resolved - hence unknown intermediates.
- name: Impaired GABA-Dependent Developmental Signaling
  description: >-
    GABA derived from GAD67 is not only a neurotransmitter: in the embryo it acts
    as a developmental signal in the formation of the secondary palate and in the
    generation of fetal movement. Its loss therefore has consequences outside the
    nervous system. This node captures the single concept of the non-neuronal
    developmental signalling deficit.
  role: mediator
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: roof of mouth development
    term:
      id: GO:0060021
      label: roof of mouth development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the embryonic stages, GAD67 is the major isoform that plays a pivotal
      role in neuronal development and synaptogenesis, as well as in the normal
      development of the palate and fetal movements.
    explanation: >-
      States GAD67's developmental role in palate formation and fetal movement,
      the two extraneural arms curated here. Evidence source is OTHER because
      this is the review portion of the paper rather than its own case data.
  - reference: PMID:9177246
    reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      this is the first demonstration of a role for GAD67-derived GABA in the
      development of nonneural tissue
    explanation: >-
      The Gad1-null mouse established that GAD67-derived GABA has a required role
      in non-neural (palatal) development.
  downstream:
  - target: Orofacial and Ventral Wall Malformation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Failure of GABA-dependent palatal shelf fusion produces cleft palate; the
      steps between GABA signalling and shelf fusion are not established.
  - target: Reduced Fetal Movement and Joint Contractures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced GABA-dependent fetal movement is the proposed route to congenital
      contractures and talipes; the causal chain is inferred from the phenotype
      and GAD67's role in fetal movement rather than measured.
- name: Orofacial and Ventral Wall Malformation
  description: >-
    Cleft palate is the characteristic malformation, present in a majority of
    reported patients, and a minority also have an omphalocele. This is the human
    counterpart of the lethal cleft palate of the Gad1-null mouse. This node
    captures the single concept of the congenital structural malformations.
  role: consequence
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: roof of mouth development
    term:
      id: GO:0060021
      label: roof of mouth development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven patients presented a cleft palate and two also had an omphalocele,
      reproducing the phenotype of the knockout Gad1-/- mouse model.
    explanation: >-
      Documents cleft palate and omphalocele in the founding cohort and their
      correspondence with the mouse null phenotype.
- name: Reduced Fetal Movement and Joint Contractures
  description: >-
    Joint contractures and talipes equinovarus are frequent, and are attributed to
    reduced fetal movement rather than to a primary skeletal defect. This node
    captures the single concept of the fetal-akinesia-type musculoskeletal
    consequence.
  role: consequence
  biological_scale: ORGANISM
  locations:
  - preferred_term: skeletal joint
    term:
      id: UBERON:0000982
      label: skeletal joint
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight patients had joint contractures and/or pes equinovarus.
    explanation: >-
      Documents contractures and pes equinovarus in the majority of the founding
      cohort.
- name: Developmental Encephalopathy
  description: >-
    Developmental impairment is severe to profound in every reported patient bar
    one, who had moderate intellectual disability and was ambulant; the rest were
    bed-confined. About a third of the founding cohort died in early childhood.
    This node captures the single concept of the developmental and mortality
    endpoint.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients who suffered from this syndrome generally manifested severe to
      profound neurodevelopmental delay, seizures, and often congenital
      anomalies such as the cleft palate or/and omphalocele.
    explanation: >-
      Summarizes the severe-to-profound developmental phenotype across the
      published cases. Evidence source is OTHER because this statement summarizes
      the literature rather than the paper's own single case.
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four patients died before 4 years of age.
    explanation: >-
      Documents early childhood mortality in four of the eleven patients of the
      founding cohort.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Literature review revealed all reported patients, except for one patient who had moderate ID and ambulation, suffered from severe to profound ID and were bed‐confined."
    explanation: >-
      Supports the severity and functional-status half of this node's claim - all
      but one reported patient severely-to-profoundly impaired and bed-confined.
      Evidence source is OTHER because this is the paper's literature summary.
phenotypes:
- name: Seizures
  description: >-
    Seizures occur in every reported patient, with onset from birth to six months
    of age.
  category: Neurological
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "All of the reported patients manifested seizures."
    explanation: >-
      A literature review across all published cases reports seizures in every
      patient, which is what carries the OBLIGATE band. Evidence source is OTHER
      because this is the paper's literature summary rather than its own case.
- name: Neonatal-Onset Seizures
  description: >-
    Seizure onset was within the first month of life in every evaluable patient of
    the founding cohort, but across the assembled literature onset ranges from
    birth to six months, so neonatal onset is characteristic rather than universal.
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 10 patients, from whom early disease history was available, presented
      with seizure onset in the first month of life, mainly consisting of
      epileptic spasms or myoclonic seizures.
    explanation: >-
      Ten patients with first-month onset, against a total published literature of
      roughly nineteen, gives a derived lower bound above 50% - the FREQUENT band
      (30-79%). A higher band is not asserted because the review below reports
      onset extending to six months.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In reported patients, the age‐onset of seizures was from the birth to 6 months old"
    explanation: >-
      Support is PARTIAL because this sentence bounds the claim rather than making
      it: onset across the published literature runs from birth to six months, so
      neonatal onset is characteristic but not universal, which is why the band is
      FREQUENT rather than higher. Evidence source is OTHER because this is the
      paper's literature summary. The quote carries a U+2010 hyphen in "age-onset"
      and a U+2009 thin space before "months", copied verbatim from the source.
- name: Epileptic Spasms
  description: >-
    Epileptic (infantile) spasms are one of the two predominant early seizure
    semiologies.
  category: Neurological
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mainly consisting of epileptic spasms or myoclonic seizures
    explanation: Names epileptic spasms as a predominant early semiology.
- name: Myoclonic Seizures
  description: >-
    Myoclonic seizures are the other predominant early seizure semiology.
  category: Neurological
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mainly consisting of epileptic spasms or myoclonic seizures
    explanation: Names myoclonic seizures as a predominant early semiology.
- name: Focal Motor Seizures
  description: Focal motor seizures are among the reported semiologies.
  category: Neurological
  phenotype_term:
    preferred_term: Focal motor seizure
    term:
      id: HP:0011153
      label: Focal motor seizure
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
    explanation: >-
      Names focal motor seizures among the reported semiologies. Evidence source
      is OTHER because this is the paper's literature summary.
- name: Bilateral Tonic-Clonic Seizures
  description: Tonic-clonic seizures are among the reported semiologies.
  category: Neurological
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "and the patients showed heterogeneous types of seizures such as tonic–clonic, epileptic spasm, myoclonic, and focal motor seizures."
    explanation: >-
      Names tonic-clonic seizures among the reported semiologies. Evidence source
      is OTHER because this is the paper's literature summary.
- name: Suppression-Burst EEG
  description: >-
    Neonatal EEG shows a suppression-burst pattern or burst attenuation.
  category: Neurological
  phenotype_term:
    preferred_term: EEG with burst suppression
    term:
      id: HP:0010851
      label: EEG with burst suppression
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early EEG showed suppression-burst or pattern of burst attenuation or
      hypsarrhythmia if only recorded in the post-neonatal period.
    explanation: Documents the suppression-burst / burst-attenuation neonatal EEG.
- name: Hypsarrhythmia
  description: >-
    Hypsarrhythmia is seen when EEG is first recorded after the neonatal period.
  category: Neurological
  phenotype_term:
    preferred_term: Hypsarrhythmia
    term:
      id: HP:0002521
      label: Hypsarrhythmia
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early EEG showed suppression-burst or pattern of burst attenuation or
      hypsarrhythmia if only recorded in the post-neonatal period.
    explanation: Documents hypsarrhythmia on post-neonatal recordings.
- name: Severe to Profound Developmental Delay
  description: >-
    Global developmental impairment is severe to profound in nearly all reported
    patients.
  category: Neurological
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients who suffered from this syndrome generally manifested severe to
      profound neurodevelopmental delay, seizures, and often congenital
      anomalies such as the cleft palate or/and omphalocele.
    explanation: >-
      Summarizes severe-to-profound neurodevelopmental delay across published
      cases. Evidence source is OTHER because this is the paper's literature
      summary rather than its own case observation.
- name: Hypotonia
  description: Muscular hypotonia is a common early finding.
  category: Neurological
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The clinical investigation has shown that spasms and hypotonia are common
      among reported patients.
    explanation: >-
      States that hypotonia is common across reported patients. Evidence source
      is OTHER because this is a literature summary.
- name: Absent Speech
  description: >-
    Speech was absent in the index patient of the 2023 report, consistent with the
    bed-confined, severely impaired functional status of most reported patients.
  category: Neurological
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he manifested severe neurodevelopmental delay with bed confinement, spasticity in limbs, speech absence, and incontinency."
    explanation: >-
      Documents absent speech in the index patient. No frequency band is asserted
      because this is a single-patient observation.
- name: Spasticity
  description: >-
    Limb spasticity was present in the index patient of the 2023 report.
  category: Neurological
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he manifested severe neurodevelopmental delay with bed confinement, spasticity in limbs, speech absence, and incontinency."
    explanation: >-
      Documents limb spasticity in the index patient. No frequency band is
      asserted because this is a single-patient observation.
- name: Cerebral Atrophy
  description: >-
    Brain MRI is normal in most patients, but diffuse cerebral atrophy was present
    in the index patient of the 2023 report and later imaging at older ages shows
    abnormalities in some.
  category: Neurological
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI showed diffuse cerebral atrophy and severe ventriculomegaly."
    explanation: >-
      Documents cerebral atrophy on MRI in the index patient. No frequency band is
      asserted because the same paper reports MRI as normal in the majority.
- name: Ventriculomegaly
  description: >-
    Severe ventriculomegaly accompanied the cerebral atrophy in the index patient
    of the 2023 report.
  category: Neurological
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI showed diffuse cerebral atrophy and severe ventriculomegaly."
    explanation: >-
      Documents ventriculomegaly on MRI in the index patient. No frequency band is
      asserted because this is a single-patient observation.
- name: Cleft Palate
  description: >-
    Cleft palate is the characteristic extraneural malformation, present in seven
    of the eleven patients of the founding cohort.
  category: Craniofacial
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven patients presented a cleft palate and two also had an omphalocele,
      reproducing the phenotype of the knockout Gad1-/- mouse model.
    explanation: Documents cleft palate in seven of eleven patients.
- name: Omphalocele
  description: >-
    Omphalocele occurs in a minority, always alongside cleft palate in the
    reported cases.
  category: Gastrointestinal
  phenotype_term:
    preferred_term: Omphalocele
    term:
      id: HP:0001539
      label: Omphalocele
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven patients presented a cleft palate and two also had an omphalocele,
      reproducing the phenotype of the knockout Gad1-/- mouse model.
    explanation: Documents omphalocele in two of eleven patients.
- name: Congenital Joint Contractures
  description: >-
    Congenital contractures, reported as arthrogryposis in some patients, are
    frequent and are attributed to reduced fetal movement.
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Congenital contracture
    term:
      id: HP:0002803
      label: Congenital contracture
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight patients had joint contractures and/or pes equinovarus.
    explanation: Documents joint contractures in eight of eleven patients.
- name: Talipes Equinovarus
  description: >-
    Pes equinovarus (club foot) accompanies the joint contractures in many
    patients.
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Talipes equinovarus
    term:
      id: HP:0001762
      label: Talipes equinovarus
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight patients had joint contractures and/or pes equinovarus.
    explanation: Documents pes equinovarus in the founding cohort.
- name: Scoliosis
  description: >-
    Scoliosis is among the recurrent dysmorphic and skeletal findings in the
    assembled literature series.
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common dysmorphological symptoms in these patients included scoliosis,
      cleft palate, omphalocele, club foot, plagiocephaly, and arthrogryposis.
    explanation: >-
      Lists scoliosis among the recurrent dysmorphic findings. Evidence source is
      OTHER because this is the paper's literature summary.
- name: Plagiocephaly
  description: >-
    Plagiocephaly is among the recurrent dysmorphic findings in the assembled
    literature series.
  category: Craniofacial
  phenotype_term:
    preferred_term: Plagiocephaly
    term:
      id: HP:0001357
      label: Plagiocephaly
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common dysmorphological symptoms in these patients included scoliosis,
      cleft palate, omphalocele, club foot, plagiocephaly, and arthrogryposis.
    explanation: >-
      Lists plagiocephaly among the recurrent dysmorphic findings. Evidence
      source is OTHER because this is the paper's literature summary.
genetic:
- name: GAD1
  gene_term:
    preferred_term: GAD1
    term:
      id: hgnc:4092
      label: GAD1
  relationship_type: CAUSATIVE
  notes: >-
    GAD1 (2q31.1, 21 exons) encodes GAD67. Reported pathogenic alleles include
    missense, nonsense, splice-site and in-frame deletion variants distributed
    across the protein, including the PLP-binding domain. A recurrent nonsense
    allele, c.1591C>T p.(Arg531*), has been seen in several unrelated
    populations.
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The recurrent c.1591C>T, p.(Arg531*) variant has been reported three times
      (20% of all reported variants) in different populations, indicating it may
      be a probable hotspot mutation.
    explanation: >-
      Documents the recurrent p.(Arg531*) nonsense allele and its share of
      reported variants.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The mutation is located in the PLP‐binding domain, which is important for the activity of the protein"
    explanation: >-
      Locates a reported missense allele in the pyridoxal-phosphate-binding
      domain, the structural basis on which missense alleles are argued to impair
      catalysis. Evidence source is COMPUTATIONAL because the functional inference
      rests on docking and molecular-dynamics simulation, not an enzyme assay.
diagnosis:
- name: Molecular Genetic Testing
  description: >-
    The diagnosis rests on identification of biallelic pathogenic GAD1 variants,
    typically by exome sequencing, in an infant with neonatal-onset epileptic
    encephalopathy. There is no specific biochemical marker in routine use;
    metabolic screening was normal in the reported case where it was performed.
  evidence:
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings highlight an important role for GAD1 in seizure induction,
      neuronal and extraneuronal development, and introduce GAD1 as a new gene
      associated with developmental and epileptic encephalopathy.
    explanation: >-
      Establishes GAD1 as the gene to be tested in this presentation; the
      diagnosis is molecular.
- name: Neuroimaging
  description: >-
    Brain MRI is normal in most patients early on; later imaging at older ages can
    show atrophic change, so a normal early MRI does not argue against the
    diagnosis.
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The majority of the patients had normal MRI, although, in some patients,
      later MRI at older ages revealed defects.
    explanation: >-
      Records that MRI is usually normal initially with later abnormalities in
      some. Evidence source is OTHER because this is the paper's literature
      summary.
treatments:
- name: Vigabatrin
  description: >-
    Vigabatrin irreversibly inhibits GABA transaminase, the enzyme that degrades
    GABA, and is therefore a mechanistically rational attempt to raise whatever
    GABA the residual synthetic capacity produces. Five of seven patients in the
    founding cohort who tried it had a good seizure response, but the authors
    themselves cautioned that the responders were particularly those with
    epileptic spasms, so the effect may be semiology-driven rather than
    GAD1-specific.

    The rationale has a published objection, and it is a mechanistic one rather
    than a null trial result: sparing GABA from degradation cannot help much when
    synthesis is the step that has failed, since GAD67 supplies over 90% of basal
    GABA. The 2023 review states that vigabatrin is therefore not a suitable
    solution "at least for mutations that result in severe reduction or complete
    loss of the enzyme function" - a genotype-stratified claim, which is the same
    residual-activity axis this entry records as an open gap. Two treated
    patients, including one on the vigabatrin-plus-ketogenic-diet combination,
    continued to have seizures. Both sides are curated as evidence below rather
    than resolved here, because the objection is an inference from the mechanism
    and the response is an observation, and neither refutes the other.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vigabatrin
      term:
        id: CHEBI:63638
        label: vigabatrin
  target_mechanisms:
  - target: GABA Depletion
    treatment_effect: RESTORES
    description: >-
      Blocking GABA catabolism is intended to raise the available GABA pool and
      partially offset the synthetic deficit. The link is mechanistic rationale
      plus an observed clinical seizure response, not a measured rise in human
      brain GABA.
    evidence:
    - reference: PMID:33169137
      reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Both treatment strategies are thought to increase the available pool of
        GABA, and combined they might compensate for the severely impaired GABA
        synthesis.
      explanation: >-
        States the intended mechanism - raising the available GABA pool to
        compensate for impaired synthesis - for vigabatrin and the ketogenic diet.
    - reference: PMID:37029735
      reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
      supports: REFUTE
      evidence_source: OTHER
      snippet: "it seems that prescribing vigabatrin for patients with GAD1 deficiency is not a suitable solution, at least for mutations that result in severe reduction or complete loss of the enzyme function."
      explanation: >-
        The direct argument against this link. Because GAD67 supplies most basal
        GABA, blocking catabolism has little left to spare where the variant
        abolishes synthesis, so the restorative effect is expected to fail for
        null and severe-reduction alleles. `treatment_effect` remains RESTORES
        because that is the intended mechanism the drug is chosen for; this item
        records that the intent is disputed on mechanistic grounds. Evidence
        source is OTHER because this is the paper's reasoning over the literature
        rather than a measurement.
  evidence:
  - reference: PMID:33169137
    reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In our report, five of seven patients who tried vigabatrin showed a
      remarkably good seizure response.
    explanation: >-
      Reports the vigabatrin response rate in the founding cohort. Support is
      PARTIAL because the same authors attribute the response partly to seizure
      type (epileptic spasms) rather than to the GAD1 genotype.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: REFUTE
    evidence_source: OTHER
    snippet: "regardless of the taking of the combination of vigabatrin and ketogenic diet, continued to suffer from epilepsy."
    explanation: >-
      The clinical counterweight to that response rate: the 2023 index patient and
      a patient from the independent series both continued to have seizures on the
      vigabatrin-plus-ketogenic-diet combination. Evidence source is OTHER because
      this is the paper's summary of published cases alongside its own.
- name: Ketogenic Diet
  description: >-
    The ketogenic diet is used alongside vigabatrin on the same rationale of
    increasing the available GABA pool. Its disease-specific evidence is a single
    treated infant with an excellent outcome set against at least two patients on
    the same combination who remained refractory.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Ketogenic Diet
    term:
      id: NCIT:C173168
      label: Ketogenic Diet
  target_mechanisms:
  - target: GABA Depletion
    treatment_effect: RESTORES
    description: >-
      The diet is proposed to increase the available GABA pool; this is a
      hypothesized mechanism carried over from ketogenic-diet pharmacology
      generally, not a measurement made in GAD1-deficient patients.
    evidence:
    - reference: PMID:33169137
      reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Both treatment strategies are thought to increase the available pool of
        GABA, and combined they might compensate for the severely impaired GABA
        synthesis.
      explanation: >-
        States the intended GABA-raising mechanism shared by the ketogenic diet
        and vigabatrin.
  evidence:
  - reference: PMID:33169137
    reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient (Patient C) also appears to take a combination of ketogenic
      diet and vigabatrin at the age of 28 months, and still has refractory
      seizures and severe delay.
    explanation: >-
      Records a treated patient who remained refractory on the same combination.
      Support is PARTIAL because the disease-specific evidence for the diet
      points in both directions.
- name: Early Combined Vigabatrin and Ketogenic Diet
  description: >-
    Combination therapy started in the second month of life, immediately after
    genetic diagnosis, was reported in one infant to stop seizures within two days
    and leave growth and psychomotor development unremarkable at 7 months - a
    striking exception in a disorder where a neonatal burst-suppression EEG has
    otherwise predicted profound delay. It is one observation, and another patient
    on the same combination started later remained refractory.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vigabatrin
      term:
        id: CHEBI:63638
        label: vigabatrin
  evidence:
  - reference: PMID:33169137
    reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This combination treatment not only resulted in clinical cessation of
      seizures within 2 days, but at 7 months of age, growth and psychomotor
      development were unremarkable.
    explanation: >-
      Reports the single favourable outcome on early combination therapy. Support
      is PARTIAL because the same commentary explicitly cautions against drawing
      conclusions from one observation.
  - reference: PMID:33169137
    reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      While this is certainly a reasonable hypothesis, one should be cautious
      drawing conclusions from one single observation.
    explanation: >-
      The authors' own caution about the strength of the single-patient
      developmental-outcome claim.
  target_mechanisms:
  - target: GABA Depletion
    treatment_effect: RESTORES
    description: >-
      Both components are proposed to raise the available GABA pool - vigabatrin
      by blocking GABA catabolism, the ketogenic diet by shifting substrate
      availability - so the combination is directed at the same depletion node
      each single agent targets. The effect is an inferred mechanism, not a
      measured rise in human brain GABA.
    evidence:
    - reference: PMID:33169137
      reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Both treatment strategies are thought to increase the available pool of
        GABA, and combined they might compensate for the severely impaired GABA
        synthesis.
      explanation: >-
        The authors' stated rationale for combining the two agents, directed at
        the GABA pool. Graded OTHER because it is mechanistic reasoning rather
        than a patient observation, and PARTIAL because no measurement of GABA
        in treated patients is reported.
- name: Individualized Antiseizure Medication
  description: >-
    No single antiseizure medication has emerged as the treatment of choice.
    Across the patients whose epilepsy was controlled there was no drug in
    common, so regimen choice remains empirical.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we found that there was no common drug therapy among patients whose
      epilepsy was controlled
    explanation: >-
      Documents the absence of a shared effective drug across controlled cases,
      supporting individualized rather than protocolized therapy.
animal_models:
- name: Gad1-null mouse (GAD67 knockout)
  species: Mouse
  genotype: Gad1 (GAD67) homozygous null
  publication: PMID:9177246
  description: >-
    Targeted disruption of exon 1 of mouse Gad1 abolishes GAD67. Homozygotes are
    born at Mendelian frequency but die on the first morning after birth with
    severe cleft palate, and cortical GABA is reduced to 7% of wild type. Because
    death is neonatal, the model cannot be used to study the epilepsy that defines
    the human disorder.
  evidence:
  - reference: PMID:9177246
    reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These mice were born at the expected frequency but died of severe cleft
      palate during the first morning after birth.
    explanation: >-
      Establishes the model and its neonatal lethal cleft-palate phenotype, which
      is what makes it informative for the malformation arm and uninformative for
      the epilepsy arm.
  modeled_mechanisms:
  - target: GABA Depletion
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Direct biochemical measurement of the depletion: cortical GAD activity
      under 20% and GABA content 7% of wild type in newborn nulls.
    limitations: >-
      Measured in newborn mouse cerebral cortex; the equivalent measurement has
      not been made in human patients, so the magnitude is transferred by
      inference.
    readouts:
    - name: Cerebral cortical GABA content
      target: GABA Depletion
      description: >-
        HPLC measurement of GABA in cerebral cortex homogenate of P0.5 nulls
        against wild-type littermates.
      direction: DECREASED
      interpretation: >-
        GABA at 7% of wild type is the quantitative correlate of the depletion
        node.
      evidence:
      - reference: PMID:9177246
        reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          GAD activities and GABA contents were reduced to 20% and 7%,
          respectively, in the cerebral cortex of the newborn GAD67 -/- mice.
        explanation: Reports the cortical GAD activity and GABA measurements.
    evidence:
    - reference: PMID:9177246
      reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        GAD activities and GABA contents were reduced to 20% and 7%,
        respectively, in the cerebral cortex of the newborn GAD67 -/- mice.
      explanation: >-
        Supports treating the null mouse as informative for the GABA-depletion
        node.
  - target: Orofacial and Ventral Wall Malformation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      All homozygous nulls have severe cleft palate, the same malformation seen in
      the majority of human patients. This correspondence is what the human
      founding cohort explicitly invoked.
    limitations: >-
      The mouse cleft palate is fully penetrant and lethal, whereas human cleft
      palate is present in a majority but not all patients and is survivable; and
      the mouse shows no omphalocele counterpart.
    readouts:
    - name: Secondary palate fusion
      target: Orofacial and Ventral Wall Malformation
      description: >-
        Gross and histological examination of the upper jaw and coronal facial
        sections in newborn and E17.5 animals.
      direction: ABOLISHED
      interpretation: >-
        Complete failure of secondary palate formation in every homozygote is the
        structural readout for this node.
      evidence:
      - reference: PMID:9177246
        reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Severe cleft palate was found in all homozygous mutants
        explanation: Reports full penetrance of the cleft palate readout.
    evidence:
    - reference: PMID:32282878
      reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Seven patients presented a cleft palate and two also had an omphalocele,
        reproducing the phenotype of the knockout Gad1-/- mouse model.
      explanation: >-
        The human study itself identifies the mouse null as reproducing the
        patients' malformation phenotype, which is what makes the model
        informative for this node.
  - target: Early-Onset Epileptic Seizures
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The defining human phenotype - neonatal epilepsy - cannot be observed in
      this model. Homozygotes die within a day of birth from the cleft palate, and
      their brains show no discernible structural defect, so the model gives no
      information about the seizure phenotype.
    limitations: >-
      This is a negative result by inaccessibility rather than by measurement: the
      animals do not survive long enough for an epilepsy phenotype to develop or
      be recorded, and no EEG was obtained. It should not be read as evidence that
      GAD67 loss fails to cause seizures.
    evidence:
    - reference: PMID:32705143
      reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        as Gad1-/- mice die neonatally of severe cleft palate, it has not been
        possible to determine any potential neurological dysfunction
      explanation: >-
        States explicitly that neonatal lethality prevents the mouse from
        informing the neurological phenotype.
    - reference: PMID:9177246
      reference_title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Their brain, however, did not show any discernible defects.
      explanation: >-
        The original report found no brain abnormality in the nulls, consistent
        with the model being uninformative about the neurological phenotype.
- name: Gad1-null rat
  species: Rat
  genotype: Gad1 homozygous knockout
  publication: PMID:37830095
  description: >-
    Unlike the mouse, Gad1-null rats survive to adulthood and can be recorded by
    chronic EEG. They show abundant spike-wave discharges from two months of age
    and reduced GABA immunoreactivity in reticular thalamic neuronal somata. The
    seizure phenotype is absence-type spike-wave discharge, not the neonatal
    spasms and suppression-burst pattern of the human disorder.
  evidence:
  - reference: PMID:37830095
    reference_title: "Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      SWDs were abundant in EEG from Gad1 (-/-) rats as young as 2 months old.
    explanation: >-
      Establishes that this model, unlike the mouse, survives to yield an
      electrographic seizure phenotype.
  modeled_mechanisms:
  - target: Neuronal Hyperexcitability and Hypersynchrony
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      GAD1 loss in the rat produces a hypersynchronous electrographic phenotype,
      supporting the general link from GABA synthesis failure to network
      hypersynchrony.
    limitations: >-
      The discharge type is absence-like spike-wave activity in adolescent and
      adult animals, mechanistically a thalamocortical oscillation, rather than
      the neonatal epileptic spasms and suppression-burst background that define
      the human disease. Common laboratory rat strains also show spike-wave
      discharges spontaneously, so the phenotype is a shift in severity against a
      noisy background rather than an all-or-none disease model. Valproate, which
      suppressed discharges in controls, made them worse in the nulls, so drug
      responses in this model should not be transferred to patients.
    readouts:
    - name: Reticular thalamic somatic GABA immunoreactivity
      target: Neuronal Hyperexcitability and Hypersynchrony
      description: >-
        Immunohistochemistry for GABA in reticular thalamic nucleus neurons of
        null versus control rats.
      direction: DECREASED
      interpretation: >-
        Confirms that the electrographic phenotype is accompanied by the expected
        loss of GABA in the implicated inhibitory nucleus.
      evidence:
      - reference: PMID:37830095
        reference_title: "Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          GABA immunoreactivity was significantly reduced in the somata of RTN
          neurons in Gad1 (-/-) rats but not in their axons targeting the
          thalamus.
        explanation: Reports the immunohistochemical GABA measurement.
    evidence:
    - reference: PMID:37830095
      reference_title: "Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        VPA treatment alleviated SWD symptoms in control rats, however,
        counterintuitively exacerbated the symptoms in Gad1 (-/-) rats.
      explanation: >-
        The paradoxical valproate response is why this model is treated as only
        partially informative and its pharmacology is not transferred to patients.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Fewer than twenty patients have been reported since the syndrome was defined
    in 2020: eleven in the founding cohort, six in an independent series, and
    isolated further cases. No population rate has been estimated, and no
    frequency band is asserted here.
  evidence:
  - reference: PMID:32282878
    reference_title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we describe a new syndromic developmental and epileptic
      encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as
      presented by 11 patients from six independent consanguineous families.
    explanation: >-
      Provides the founding literature case count; no normalized population rate
      is asserted.
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we present six affected individuals from six unrelated families,
      carrying bi-allelic GAD1 variants
    explanation: Adds six further reported patients to the literature count.
datasets: []
discussions:
- discussion_id: gap_dee89_missense_sparing_of_malformations
  prompt: >-
    Do GAD1 missense variants genuinely spare palatal and ventral wall
    development, and if so is that because they retain residual decarboxylase
    activity above a developmental threshold that truncating alleles fall below?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Orofacial and Ventral Wall Malformation
  - pathophysiology#Impaired GABA-Dependent Developmental Signaling
  rationale: >-
    Across the published cases, patients carrying missense variants had neither
    cleft palate nor omphalocele while their neurological phenotype was
    indistinguishable from that of truncating-variant patients. A dose threshold
    that development clears but neuronal inhibition does not would explain the
    pattern, but no residual-activity measurements exist for the human alleles,
    and the observation rests on a small number of published case reports rather
    than a systematic cohort. It is recorded here rather than curated as an
    allelic subtype for that reason.
  proposed_experiments:
  - experiment_id: exp_dee89_gad1_missense_residual_activity
    name: Residual decarboxylase activity of patient GAD1 missense alleles
    description: >-
      Express the reported missense alleles alongside truncating alleles and wild
      type, and measure glutamate decarboxylase activity and GABA production, to
      test whether the missense alleles retain measurable residual activity.
  evidence:
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the comparison of clinical symptoms between patients with missense and
      truncating mutations did not show any significant clinical difference,
      except that patients with missense mutations did not show cleft palates or
      omphaloceles.
    explanation: >-
      States the allelic observation this gap is about: malformations absent in
      missense-variant patients, neurological phenotype unchanged.
- discussion_id: mismatch_dee89_gad1_null_mouse_neonatal_lethality
  prompt: >-
    Can any Gad1-loss animal model inform the neurological arm of DEE 89, given
    that the mouse null dies of cleft palate before an epilepsy phenotype can
    emerge and the surviving rat null has a mechanistically different seizure
    type?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Early-Onset Epileptic Seizures
  - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
  rationale: >-
    The malformation arm of this disorder has an excellent model and the
    neurological arm effectively has none. Gad1-null mice die on the first day of
    life from cleft palate with no discernible brain defect, so the epilepsy is
    inaccessible; Gad1-null rats survive but show absence-type spike-wave
    discharges from two months of age, a thalamocortical oscillation rather than
    the neonatal spasms with suppression-burst background that define the human
    disease - and valproate, which helps control rats, worsens the nulls. The
    mismatch matters because it is exactly the arm where a preclinical model
    would be used to test the vigabatrin and ketogenic-diet rationale.
  proposed_experiments:
  - experiment_id: exp_dee89_palate_rescued_gad1_mouse_eeg
    name: Palate-rescued conditional Gad1 mouse with neonatal EEG
    description: >-
      Generate a Gad1 null with palatal development rescued (for example by
      tissue-restricted expression), so that homozygotes survive the neonatal
      period, and record EEG through the neonatal and infantile period to
      establish whether a suppression-burst and spasm phenotype develops.
  evidence:
  - reference: PMID:32705143
    reference_title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      as Gad1-/- mice die neonatally of severe cleft palate, it has not been
      possible to determine any potential neurological dysfunction
    explanation: States the inaccessibility of the neurological phenotype in the mouse null.
  - reference: PMID:37830095
    reference_title: "Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      VPA treatment alleviated SWD symptoms in control rats, however,
      counterintuitively exacerbated the symptoms in Gad1 (-/-) rats.
    explanation: >-
      The rat null's paradoxical drug response illustrates why its pharmacology
      cannot be transferred to patients.
- discussion_id: gap_dee89_early_combination_therapy_and_developmental_outcome
  prompt: >-
    Does starting vigabatrin plus a ketogenic diet in the first weeks after
    genetic diagnosis change developmental outcome in DEE 89, or only seizure
    frequency?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Developmental Encephalopathy
  - pathophysiology#GABA Depletion
  rationale: >-
    One infant started on the combination in the second month of life had
    seizures stop within two days and normal growth and psychomotor development at
    7 months, which is remarkable against a cohort in which every patient with a
    neonatal burst-suppression EEG had profound delay. But a second patient on the
    same combination, started later, remained refractory with severe delay, and
    the commentary authors explicitly caution against generalizing from a single
    case. Because the disorder is ultra-rare and the window appears to be narrow,
    the question is unlikely to be settled by a conventional trial and needs a
    prospective registry with a pre-specified developmental endpoint.

    There is also a mechanistic objection that any such registry would have to
    stratify for. Vigabatrin works by blocking GABA catabolism, so it can only
    spare GABA that is being made; where the variant abolishes GAD67 activity
    there is little to spare, and the 2023 review argues on that basis that
    vigabatrin is not a suitable solution for severe-reduction or complete-loss
    alleles. That makes residual enzyme activity - the same quantity the allelic
    knowledge gap in this entry asks about - the plausible determinant of who
    responds, and it is not measured in any reported patient. The same review
    notes that oral GABA does not cross the blood-brain barrier but that
    brain-penetrant GABA derivatives might, which is the alternative route if the
    catabolism-blocking rationale really does fail at low residual activity.
  proposed_experiments:
  - experiment_id: exp_dee89_treat_on_diagnosis_registry
    name: Prospective treat-on-diagnosis registry with developmental endpoints
    description: >-
      Enrol newly genetically diagnosed infants, record time from diagnosis to
      start of combination therapy, and follow standardized developmental
      assessments, so that outcome can be related to treatment latency rather
      than compared across ad hoc case reports.
  - experiment_id: exp_dee89_vigabatrin_response_by_residual_activity
    name: Vigabatrin response stratified by residual GAD67 activity
    description: >-
      For each reported allele, measure residual glutamate decarboxylase activity
      and relate it to that patient's vigabatrin response, to test the review's
      prediction that the drug fails where activity is abolished and works only
      where some synthesis remains.
  evidence:
  - reference: PMID:33169137
    reference_title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of a neonatal burst-suppression pattern on EEG generally has a
      dire prognosis, and all families reported in our study indeed had a
      profound developmental delay.
    explanation: >-
      Establishes the baseline against which the single favourable outcome stands
      out, and hence why the question is open rather than answered.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "it seems that prescribing vigabatrin for patients with GAD1 deficiency is not a suitable solution, at least for mutations that result in severe reduction or complete loss of the enzyme function."
    explanation: >-
      The genotype-stratified mechanistic objection that any prospective study
      would have to account for. Support is PARTIAL because it argues against one
      arm of the intervention rather than resolving the developmental-outcome
      question this gap asks. Evidence source is OTHER because this is the
      paper's reasoning over the literature.
  - reference: PMID:37029735
    reference_title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the production of GABA derivatives with the ability to cross the blood–brain barrier may be useful for controlling epilepsy in these patients."
    explanation: >-
      Names the alternative therapeutic route the same authors propose if the
      catabolism-blocking rationale fails - brain-penetrant GABA derivatives,
      since oral GABA does not cross the blood-brain barrier. Evidence source is
      OTHER because this is the paper's proposal rather than data.
references:
- reference: PMID:32282878
  title: "Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy."
- reference: PMID:32705143
  title: "Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants."
- reference: PMID:37029735
  title: "Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile."
- reference: PMID:33169137
  title: "Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency."
- reference: PMID:9177246
  title: "Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase."
- reference: PMID:37830095
  title: "Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment."
📚

References & Deep Research

References

6
PMID:32282878
Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy.
No top-level findings curated for this source.
PMID:32705143
Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants.
No top-level findings curated for this source.
PMID:37029735
Developmental and epileptic encephalopathy 89: A novel bi-allelic variant, molecular dynamics simulation, and a comprehensive clinical and molecular profile.
No top-level findings curated for this source.
PMID:33169137
Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency.
No top-level findings curated for this source.
PMID:9177246
Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase.
No top-level findings curated for this source.
PMID:37830095
Gad1 knock-out rats exhibit abundant spike-wave discharges in EEG, exacerbated with valproate treatment.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Developmental and Epileptic Encephalopathy 89 (DEE89): Disease Characteristics Report
Edison Scientific Literature 10 citations 2026-08-27T02:40:44.230110

Developmental and Epileptic Encephalopathy 89 (DEE89): Disease Characteristics Report

Executive summary and evidence limits

Developmental and epileptic encephalopathy 89 (DEE89) is an ultra-rare, autosomal-recessive neurodevelopmental disorder caused by biallelic loss-of-function variants in GAD1, which encodes glutamate decarboxylase 67 (GAD67), the principal enzyme supporting basal γ-aminobutyric acid (GABA) production in the central nervous system. The defining phenotype is early-infantile epilepsy followed by—or accompanied by—severe developmental impairment, hypotonia or weakness, and occasional craniofacial or skeletal abnormalities. The disease was established from only six unrelated affected individuals, so most percentages below describe that ascertainment cohort rather than population-level frequencies. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-1, OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1)

The foundational primary report is Neuray et al., “Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants,” published online 10 July 2020 in Brain, volume 143, pages 2388–2397; PMID 32282878; DOI/URL: https://doi.org/10.1093/brain/awaa178. Its abstract states: “Mice lacking GAD1 show neonatal mortality, but the human phenotype associated with GAD1 disruption is poorly characterized. Neuray et al. describe six patients with biallelic GAD1 mutations, presenting with early-infantile onset epilepsy, neurodevelopmental delay, muscle weakness and non-CNS manifestations.” No substantive 2023–2024 DEE89-specific cohort, natural-history study, treatment trial, or mechanistic patient study was identified; recent literature largely discusses DEEs generally rather than expanding this disease-specific evidence base. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-1)

Domain Evidence-based finding Evidence level/limitations
Identity/identifiers Developmental and epileptic encephalopathy 89 (DEE89) is linked to MONDO:0030856 and OMIM 619124; Open Targets shows a single associated target, GAD1, with supporting literature including PMID 32282878. The evidence base is disease-level aggregation plus a small primary human case series. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1, neuray2020earlyinfantileonsetepilepsy pages 1-1) Identifier linkage is strong, but disease characterization is based on very limited published human data.
Causal gene/inheritance DEE89 is caused by biallelic GAD1 variants encoding GAD67/glutamate decarboxylase 1; inheritance is autosomal recessive. In the reported cohort, 5/6 families had homozygous variants and 1/6 had compound heterozygous variants; 4/6 affected individuals were born to consanguineous parents. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-1) Human genetic evidence is consistent, but numbers come from only 6 unrelated families.
Foundational evidence The foundational report is Neuray et al., Brain, July 2020, DOI: 10.1093/brain/awaa178, PMID 32282878, describing 6 affected individuals from 6 unrelated families and introducing GAD1 as a new gene associated with developmental and epileptic encephalopathy. (neuray2020earlyinfantileonsetepilepsy pages 1-1, neuray2020earlyinfantileonsetepilepsy pages 3-3) Single primary series; no larger replication cohort identified in the gathered evidence.
Onset/seizures Seizure onset occurred at 2-6 months (early-infantile onset). Seizure types were predominantly focal motor seizures, with some epileptic spasms and bilateral motor seizures. Seizures were pharmacologically controlled in 3/6 and drug-resistant in 3/6. (neuray2020earlyinfantileonsetepilepsy pages 3-3) Denominators preserved from the only cohort; no standardized natural-history registry available.
Development/neuromuscular All reported individuals had severe developmental delay/intellectual disability; most had no speech or communication, with only 1/6 retaining basic/simple speech. Reduced muscle strength/weakness or hypotonia was present in 5/6. Variable extracerebral features included skeletal abnormalities, dysmorphic features, and cleft palate. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-1, neuray2020earlyinfantileonsetepilepsy pages 1-2) Core phenotype is consistent, but extracerebral manifestations are variable and based on few cases.
MRI/EEG MRI was reportedly normal in 4/6 and abnormal in 2/6, with ventricular enlargement or global atrophy. EEG abnormalities included burst-suppression, diffuse slowing with multifocal/generalized sharp waves, and hypsarrhythmia. (neuray2020earlyinfantileonsetepilepsy pages 3-3) Imaging appears nonspecific; EEG spectrum is broad and not disease-exclusive.
Variants Seven reported ultrarare germline GAD1 variants were: c.87C>G p.Tyr29Ter, c.568delC p.Gln190Serfs11, c.670delC p.Leu224Serfs5, c.971T>G p.Phe324Cys, c.1040C>T p.Thr347Met, *c.1591C>T p.Arg531, c.1691A>G p.Asn564Ser. Variant classes included nonsense, frameshift, missense; multiple alleles are predicted loss-of-function via nonsense-mediated decay or catalytic disruption. (neuray2020earlyinfantileonsetepilepsy pages 6-6, neuray2020earlyinfantileonsetepilepsy pages 5-6) Functional interpretation is strongest for null alleles; allele-frequency details were not extracted in this conversation.
Mechanism GAD1/GAD67 is the major CNS enzyme for converting glutamate to GABA and contributes about 90% of baseline GABA. Bi-allelic loss of function is inferred to reduce GABA synthesis, disturb inhibitory/excitatory balance, lower seizure threshold, and impair neurodevelopment; persistent severe disability despite seizure freedom in 3/6 supports a developmental effect beyond seizures alone. (neuray2020earlyinfantileonsetepilepsy pages 6-7, neuray2020earlyinfantileonsetepilepsy pages 6-6, neuray2020earlyinfantileonsetepilepsy pages 1-1, neuray2020earlyinfantileonsetepilepsy pages 5-6) Mechanistic chain is biologically plausible and supported by human genetics plus model data, but direct patient biochemical assays were not summarized here.
Treatment No disease-specific targeted therapy was identified. Management in the cohort was standard antiseizure treatment with 3/6 achieving seizure control and 3/6 remaining drug-resistant. No DEE89-specific clinical intervention trial was found. (neuray2020earlyinfantileonsetepilepsy pages 3-3) Evidence is limited to case-based supportive epilepsy care; no controlled treatment studies or precision therapies are available in the gathered evidence.
Epidemiology/trials No robust prevalence, incidence, or survival estimates were identified. The human literature currently consists of a very small number of published cases. Clinical trial search found no relevant DEE89/GAD1-specific interventional trials. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1, neuray2020earlyinfantileonsetepilepsy pages 3-3) Major evidence gap; epidemiology and prognosis remain undefined.
Model organism Gad1-null mice show neonatal lethality and severe cleft palate, supporting the gene’s role in development but limiting detailed postnatal neurological modeling. Animal data also support a role for GAD/GABA pathway deficiency in seizures. (neuray2020earlyinfantileonsetepilepsy pages 6-7, neuray2020earlyinfantileonsetepilepsy pages 1-1) Useful for biological plausibility, but existing model limitations reduce fidelity for full human DEE89 natural history.

Table: This table summarizes the highest-confidence evidence gathered for developmental and epileptic encephalopathy 89, preserving small-cohort denominators and highlighting where the literature is strong versus sparse. It is useful as a compact evidence map for knowledge-base curation.

1. Disease information

Definition

DEE89 is a monogenic developmental and epileptic encephalopathy in which the underlying GAD1 defect directly disrupts neurodevelopment while deficient inhibitory neurotransmission promotes epilepsy. The “developmental and epileptic” designation is important: developmental disability is not merely a consequence of recurrent seizures. In the original cohort, severe intellectual/developmental impairment persisted in all patients even though three became seizure-free, supporting parallel developmental and epileptic effects. (neuray2020earlyinfantileonsetepilepsy pages 6-6)

Identifiers and synonyms

  • MONDO: MONDO:0030856.
  • OMIM phenotype: 619124.
  • Causal gene: GAD1, Ensembl ENSG00000128683; approved name glutamate decarboxylase 1.
  • Common names: developmental and epileptic encephalopathy 89; DEE89; GAD1-related developmental and epileptic encephalopathy; GAD1-related early-infantile epilepsy and developmental delay.
  • Orphanet: no disease-specific Orphanet identifier was established in the retrieved evidence.
  • ICD-10/ICD-11: no unique DEE89 code. Cases are coded under broader genetic/developmental epileptic encephalopathy, epilepsy, intellectual disability, and developmental-disorder categories.
  • MeSH: no unique disease heading; broader headings include Epileptic Encephalopathies, Epilepsy, and Neurodevelopmental Disorders.

Open Targets links MONDO:0030856 to one associated target, GAD1, and cites PMID 32282878 plus ClinVar records, providing aggregated disease-level corroboration of the primary case-series evidence. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1)

Source granularity: available information is mainly an aggregated publication-level case series, not longitudinal EHR evidence. Database entries subsequently aggregate those individual reports.

2. Etiology, risk, and protective factors

Causal factor

The established cause is germline biallelic GAD1 variation, generally producing loss of GAD67 function. Five of six reported families had homozygous variants and one had compound-heterozygous variants. Four affected individuals were born to consanguineous parents. (neuray2020earlyinfantileonsetepilepsy pages 3-3)

Risk factors

  • Genetic: two pathogenic or likely pathogenic alleles in trans are the principal risk factor. Parental consanguinity increases the probability that both parents carry the same rare allele, but is not mechanistically required.
  • Family history: affected siblings would be expected in some families under recessive inheritance, although the founding report comprised one characterized patient per unrelated family.
  • Environmental, infectious, lifestyle, age, or sex risk: none has been demonstrated. The reported patients represented diverse ancestries—Persian, Pakistani, African American, Sudanese, Egyptian, and Turkish—arguing against restriction to one population, but the sample is too small for demographic inference. (neuray2020earlyinfantileonsetepilepsy pages 1-2)

Protective factors and gene–environment interaction

No protective allele, modifier gene, diet, exposure, or validated gene–environment interaction is known. Fever, sleep deprivation, illness, or medication nonadherence may trigger seizures in epilepsy generally, but these should not be entered as DEE89 causal factors without disease-specific evidence. Likewise, adequate vitamin B6 is required biochemically for pyridoxal-5′-phosphate-dependent decarboxylases, but neither pyridoxine deficiency nor pyridoxine responsiveness has been demonstrated as a DEE89 mechanism or treatment.

3. Phenotypes

Observed frequencies are from n=6 and therefore have very wide uncertainty.

Phenotype Character, onset/course, observed frequency Suggested HPO term
Early-infantile seizures Onset 2–6 months; focal motor seizures predominated, with epileptic spasms and bilateral motor seizures in some patients; chronic and variably treatment-resistant Seizure HP:0001250; Infantile onset HP:0003593; Focal motor seizure HP:0011153; Epileptic spasms HP:0011097
Developmental delay/intellectual disability Severe in 6/6; persistent despite seizure freedom in some; major lifelong functional effect expected Global developmental delay HP:0001263; Severe intellectual disability HP:0010864
Absent/severely impaired speech Most had no speech or effective communication; one had basic/simple language Absent speech HP:0001344; Delayed speech and language development HP:0000750
Hypotonia, weakness, poor motor control Reduced strength or hypotonia in 5/6, ranging from mild hypotonia to limited head control Muscular hypotonia HP:0001252; Muscle weakness HP:0001324; Head lag HP:0002421
Abnormal EEG Burst suppression, hypsarrhythmia, diffuse slowing, and multifocal/generalized sharp waves EEG with burst suppression HP:0010851; Hypsarrhythmia HP:0002521; EEG abnormality HP:0002353
Brain-imaging abnormality MRI normal in 4/6; ventricular enlargement or global cerebral atrophy in 2/6 Cerebral atrophy HP:0002059; Ventriculomegaly HP:0002119
Dysmorphism Variable thick eyebrows, protruding ears, wide mouth, retrognathia, infraorbital creases, or depressed nasal bridge Thick eyebrow HP:0000574; Protruding ear HP:0000411; Wide mouth HP:0000154; Retrognathia HP:0000278; Depressed nasal bridge HP:0005280
Skeletal/abdominal findings Variable scoliosis, clinodactyly, or diastasis recti Scoliosis HP:0002650; Clinodactyly HP:0030084; Diastasis recti HP:0001540
Cleft palate Reported in one patient; biologically concordant with the mouse knockout but not a universal feature Cleft palate HP:0000175

These features and frequencies derive from the original six-person series. EEG abnormalities included burst suppression, hypsarrhythmia, and diffuse slowing with multifocal or generalized sharp waves; MRI was nonspecific and often normal. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 4-5)

Quality-of-life impact: no EQ-5D, SF-36, PROMIS, caregiver-burden, or disease-specific QoL measurements have been published. Nevertheless, severe communication, motor, cognitive, and seizure impairments imply dependence for daily activities and substantial caregiver burden. That conclusion is clinical inference, not a measured DEE89 outcome.

4. Genetic and molecular information

Gene and protein

GAD1 encodes the 67-kDa glutamate decarboxylase isoform, GAD67. The protein has an N-terminal targeting/dimerization region, a central pyridoxal-5′-phosphate-binding region, and a C-terminal catalytic region. GAD67 supplies approximately 90% of constitutive basal CNS GABA, whereas GAD65 has a more activity-responsive presynaptic role. (neuray2020earlyinfantileonsetepilepsy pages 1-2, neuray2020earlyinfantileonsetepilepsy pages 1-1, neuray2020earlyinfantileonsetepilepsy pages 5-6)

Suggested annotations include HGNC:4092 (GAD1), UniProt Q99259, and enzyme class glutamate decarboxylase, EC 4.1.1.15. The biochemical reaction is L-glutamate → GABA + CO₂, requiring pyridoxal 5′-phosphate (ChEBI:18405) as cofactor; substrates/products include L-glutamate (ChEBI:29985) and 4-aminobutanoate/GABA (ChEBI:16865).

Reported disease alleles

Seven ultrarare germline variants were reported:

  1. c.87C>G, p.(Tyr29Ter) — nonsense.
  2. c.568delC, p.(Gln190SerfsTer11) — frameshift.
  3. c.670delC, p.(Leu224SerfsTer5) — frameshift.
  4. c.971T>G, p.(Phe324Cys) — missense.
  5. c.1040C>T, p.(Thr347Met) — missense.
  6. c.1591C>T, p.(Arg531Ter) — nonsense.
  7. c.1691A>G, p.(Asn564Ser) — missense. (neuray2020earlyinfantileonsetepilepsy pages 6-6)

The truncating variants are expected to cause nonsense-mediated decay or truncated protein. Missense substitutions affect conserved functional regions and were computationally predicted to impair stability or catalysis; four of seven reported alleles involved the PLP-binding domain. The aggregate disease mechanism is therefore loss of function, not gain of function or dominant-negative activity. (neuray2020earlyinfantileonsetepilepsy pages 6-6, neuray2020earlyinfantileonsetepilepsy pages 5-6)

The source paper described the variants as ultrarare and GAD1 as intolerant of damaging variation, but exact gnomAD/TOPMed allele counts and current per-variant ClinVar classifications were not available in the retrieved full-text evidence. These should be refreshed directly from ClinVar and gnomAD before production curation. Open Targets identified two associated ClinVar records, RCV006436612 and RCV004820862. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1)

Other genomic mechanisms

No disease-causing recurrent copy-number variant, translocation, inversion, repeat expansion, mitochondrial variant, somatic mosaicism, modifier gene, methylation signature, or other DEE89-specific epigenetic abnormality is established. Large deletions disrupting both GAD1 alleles would be mechanistically plausible but were not documented in the founding cohort.

5. Environmental information

DEE89 is a genetic Mendelian disease. No toxin, radiation, pollution, occupational exposure, smoking, alcohol, diet, infection, or other environmental exposure has been shown to cause it. There is no zoonotic or infectious component. Environmental conditions may alter seizure threshold nonspecifically, but no DEE89-specific interaction has been quantified.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream genetic lesion: biallelic damaging GAD1 variants produce absent or impaired GAD67.
  2. Primary biochemical defect: reduced PLP-dependent decarboxylation of glutamate to GABA.
  3. Cellular effect: diminished GABA supply in inhibitory neurons compromises inhibitory synaptic transmission and maturation of GABAergic networks.
  4. Circuit effect: excitation–inhibition imbalance and network hypersynchrony lower seizure threshold, generating early-infantile epilepsy and encephalopathic EEG patterns.
  5. Developmental effect: GABA is also a developmental signal affecting neuronal migration, synaptogenesis, and circuit maturation. Thus GAD67 deficiency can directly impair cognition and motor development independently of seizure burden.
  6. Downstream clinical manifestations: seizures, severe developmental/intellectual disability, absent speech, hypotonia/weakness, and occasionally cerebral atrophy.
  7. Extraneural development: GAD1 expression in embryonic limb mesenchyme and pharyngeal structures, together with reduced fetal movement, may contribute to skeletal abnormalities and cleft palate; the human evidence remains provisional. (neuray2020earlyinfantileonsetepilepsy pages 8-9, neuray2020earlyinfantileonsetepilepsy pages 6-7, neuray2020earlyinfantileonsetepilepsy pages 1-1)

The observation that all six patients remained severely impaired while three achieved seizure control is an important human “natural experiment”: suppressing seizures alone does not reverse the upstream neurodevelopmental defect. (neuray2020earlyinfantileonsetepilepsy pages 6-6)

Ontology-ready mechanism annotations

  • GO biological process: glutamate decarboxylation to GABA; GABA biosynthetic process (GO:0009449); gamma-aminobutyric acid signaling pathway (GO:0007214); chemical synaptic transmission (GO:0007268); regulation of membrane potential (GO:0042391); nervous-system development (GO:0007399).
  • GO molecular function: glutamate decarboxylase activity (GO:0004351); pyridoxal-phosphate binding (GO:0030170).
  • GO cellular component: cytosol (GO:0005829), neuron projection (GO:0043005), presynapse (GO:0098793).
  • Cell Ontology: neuron (CL:0000540); GABAergic neuron (CL:0000617); interneuron (CL:0000099). Particular interneuron subclasses have not been shown to be selectively vulnerable in DEE89.

There is no DEE89-specific evidence for apoptosis, autophagy, primary mitochondrial failure, immune activation, chronic inflammation, or a distinct metabolic signature beyond deficient GABA biosynthesis. No patient-derived transcriptomics, proteomics, metabolomics, lipidomics, single-cell, spatial-transcriptomic, multi-omic, CRISPR-screen, iPSC, or organoid study was found.

7. Anatomical structures affected

The central nervous system is primary, especially neuronal networks of the cerebral cortex and other GABAergic circuits. Suggested anatomy terms are brain (UBERON:0000955), cerebral cortex (UBERON:0000956), central nervous system (UBERON:0001017), and synapse (UBERON:0001035). No consistent focal lesion or lateralization has been reported; effects are presumed bilateral and network-wide.

Secondary or variably involved structures include skeletal muscle function, axial skeleton, digits, palate, and craniofacial structures. Weakness may reflect central hypotonia rather than primary myopathy; biopsy or EMG evidence for a muscle-intrinsic lesion is absent. Relevant subcellular sites are cytosol and inhibitory synaptic compartments, not mitochondria, lysosome, or nucleus as primary disease organelles. (neuray2020earlyinfantileonsetepilepsy pages 8-9, neuray2020earlyinfantileonsetepilepsy pages 3-3)

8. Temporal development and natural history

  • Prenatal/congenital: most affected infants were not recognized prenatally; cleft palate or skeletal abnormalities may be congenital in a minority.
  • Onset: seizures began at 2–6 months, an early-infantile, generally subacute presentation.
  • Early course: epileptic spasms, focal motor seizures, or bilateral motor seizures occur with markedly abnormal EEG.
  • Later course: severe developmental delay, speech impairment, and weakness become prominent. Seizures may remit with medication or remain drug-resistant.
  • Duration: presumed lifelong. No validated staging system exists.
  • Remission: seizure freedom occurred in 3/6, but developmental disability persisted; 3/6 remained drug-resistant. (neuray2020earlyinfantileonsetepilepsy pages 3-3)

No longitudinal cohort defines progression rate, regression frequency, adult phenotype, critical therapeutic window, or late complications. Early infancy is nevertheless a plausible intervention window because both seizures and GABA-dependent circuit development are active then; this remains expert mechanistic inference rather than trial evidence.

9. Inheritance and population

Inheritance

Inheritance is autosomal recessive. For two confirmed heterozygous carrier parents, each pregnancy has an expected 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of an unaffected non-carrier. Penetrance for clearly biallelic null or severely damaging genotypes appears high, but cannot be estimated formally. Expressivity is variable, particularly for seizure control, MRI abnormalities, weakness, and extracerebral features.

There is no evidence for anticipation. Germline mosaicism is not required to explain recurrence but remains a theoretical residual risk if a variant appears de novo. No founder effect or carrier-frequency estimate is established. Consanguinity was present in 4/6 founding families, reflecting recessive ascertainment rather than proof of a population-specific disease. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-2)

Epidemiology

No prevalence, incidence, sex ratio, life-table, regional distribution, or ancestry-specific rate is available. Six ethnically diverse unrelated cases were reported initially. DEE89 should therefore be described as ultra-rare, prevalence unknown, not assigned a numerical population rate. (neuray2020earlyinfantileonsetepilepsy pages 1-2)

10. Diagnostics

Clinical evaluation

Suspect DEE89 in an infant with seizures beginning in the first months of life, severe developmental delay or stagnation, hypotonia/weakness, and an encephalopathic EEG—particularly with consanguinity or affected siblings. EEG documents seizure type and background severity but is not specific. Brain MRI evaluates structural causes and complications; a normal MRI does not exclude DEE89 because 4/6 reported scans were normal. Routine blood, urine, CSF, enzyme, or tissue biomarkers have not been validated. (neuray2020earlyinfantileonsetepilepsy pages 3-3)

Molecular confirmation

  1. Use a comprehensive developmental-epilepsy panel including GAD1, trio exome sequencing, or trio genome sequencing.
  2. Confirm candidate variants by an orthogonal method and establish trans phase through parental testing.
  3. Evaluate sequence variants, exon-level deletions/duplications, splice variants, and—if WGS/RNA studies are available—deep intronic or regulatory defects.
  4. Apply ACMG/AMP criteria using population rarity, predicted loss of function, segregation, phenotype concordance, and functional evidence.

WES was effective in the founding families. WGS can add CNV, structural, noncoding, and difficult-splice detection. CMA may be appropriate in unexplained developmental delay but will usually miss small GAD1 variants; karyotype and FISH have no disease-specific role. Mitochondrial and repeat-expansion tests are guided by the differential diagnosis, not DEE89 itself. No diagnostic RNA-seq, proteomic, metabolomic, epigenomic, or liquid-biopsy signature is validated.

Differential diagnosis

Important alternatives include other early-infantile DEEs—STXBP1, KCNQ2, SCN2A, SCN8A, CDKL5, KCNT1, DNM1, AP2M1, WWOX, PCDH12, and metabolic epilepsies such as ALDH7A1/PNPO-related vitamin-B6-dependent epilepsy. Structural brain disease, congenital infection, hypoxic injury, and inborn errors of metabolism should be assessed clinically. DEE89 is distinguished by confirmed biallelic GAD1 pathogenic variants; no electroclinical feature is pathognomonic.

Screening

DEE89 is not on routine newborn-screening panels, and no validated biochemical newborn marker exists. Targeted carrier, cascade, prenatal, or preimplantation testing is appropriate once familial variants are known.

11. Outcome and prognosis

No five- or ten-year survival, mortality rate, life expectancy, SUDEP incidence, or adult-outcome estimate exists. Gad1-null mouse neonatal lethality must not be extrapolated directly to humans with hypomorphic or partial-loss alleles.

Known morbidity is substantial: severe intellectual and communication disability occurred in all six original patients; weakness/hypotonia occurred in five; and half had drug-resistant epilepsy. Prognostic separation based on variant class is not yet possible. Seizure control does not guarantee cognitive recovery, because severe disability persisted in seizure-free patients. Potential complications follow from severe DEE generally—status epilepticus, aspiration, feeding difficulty, contractures/scoliosis, immobility, medication adverse effects, and SUDEP risk—but disease-specific rates are unknown. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 6-6)

12. Treatment

Current management

There is no approved GAD1- or DEE89-specific therapy. Management should be multidisciplinary:

  • Antiseizure medication: individualized by seizure type and EEG; 3/6 founding patients achieved pharmacological control and 3/6 were drug-resistant. Published evidence does not support one drug as uniquely effective. (neuray2020earlyinfantileonsetepilepsy pages 3-3)
  • Rescue planning: emergency benzodiazepine plan and education regarding prolonged seizures/status epilepticus.
  • Developmental care: early physical, occupational, speech/augmentative-communication, and feeding therapies.
  • Orthopedic and nutritional care: surveillance for scoliosis, contractures, aspiration, poor growth, and need for adaptive equipment.
  • Safety: seizure precautions and counseling regarding SUDEP.

Possible NCIt mappings include Anticonvulsant Agent (C264), Physical Therapy (C15308), Occupational Therapy (C15310), Speech Therapy (C15312), Genetic Counseling (C15246), and Palliative/Supportive Care (C15292); exact NCIt codes should be verified against the current release before database import.

Precision and experimental therapies

No DEE89-specific gene replacement, CRISPR editing, ASO, mRNA, cell therapy, or targeted small-molecule program has entered clinical trials, and the retrieved ClinicalTrials.gov search found no relevant interventional study. Increasing GAD1 expression, replacing GAD67, stabilizing residual enzyme, or augmenting GABAergic signaling are conceptual strategies, but chronic nonspecific GABA enhancement can cause sedation and may not restore early developmental signaling. Pyridoxine or PLP should not be represented as evidence-based DEE89 therapy absent biochemical deficiency or a supervised diagnostic trial for vitamin-B6-dependent epilepsy.

No pharmacogenomic response marker, response rate beyond the six-person series, treatment algorithm, or controlled adverse-event dataset exists.

13. Prevention

  • Primary prevention: the sporadic occurrence of recessive alleles cannot be prevented by lifestyle or vaccination. Reproductive carrier testing, preimplantation genetic testing, chorionic-villus sampling, or amniocentesis can prevent or identify recurrence in families with known variants.
  • Secondary prevention: no population screening program exists. Rapid genomic testing in early infantile DEE can shorten the diagnostic odyssey and support early seizure treatment and developmental intervention.
  • Tertiary prevention: optimize seizure control, rescue therapy, vaccination and infection management, nutrition, aspiration precautions, mobility, bone health, communication support, and orthopedic surveillance.
  • Counseling: offer parental testing, recurrence-risk counseling, cascade testing of adult relatives, and discussion of reproductive options.

There is no vaccine, environmental remediation, behavioral prophylaxis, or preventive medication specific to DEE89.

14. Other species and natural disease

No naturally occurring veterinary GAD1-associated syndrome equivalent to human DEE89 was identified, and there is no infectious transmission or zoonotic potential. Orthologs are evolutionarily conserved in vertebrates, including mouse Gad1 and zebrafish gad1b, reflecting conservation of GABA synthesis. Natural breed associations and Vertebrate Breed Ontology annotations are unavailable.

15. Model organisms

Mouse

Constitutive Gad1-null mice develop severe cleft palate and die neonatally. This strongly supports GAD1’s developmental and craniofacial roles but prevents characterization of postnatal seizures, cognition, and long-term disease progression. More generally, disruption of GAD enzymes or GABA-A receptor components can produce spontaneous seizures, supporting the proposed inhibitory-network mechanism. (neuray2020earlyinfantileonsetepilepsy pages 6-7, neuray2020earlyinfantileonsetepilepsy pages 1-1)

Suggested taxonomy is Mus musculus, NCBI Taxon 10090. Useful future models would include conditional interneuron-specific knockouts, hypomorphic or patient-variant knock-ins, and temporally controlled alleles that survive beyond birth.

Other model systems

No DEE89-specific zebrafish, Drosophila, C. elegans, patient-iPSC, neuronal culture, cerebral organoid, or humanized model was identified in the retrieved literature. These represent high-priority gaps. Patient-variant knock-in neurons could quantify GABA production, firing, synaptic inhibition, and rescue by gene replacement or residual-function modulators.

Current expert assessment and knowledge-base recommendations

DEE89 has a compelling gene–disease relationship because multiple unrelated families carried biallelic ultrarare damaging GAD1 variants, the phenotype matches loss of inhibitory neurotransmission, and the mouse knockout supports developmental consequences. Nevertheless, clinical validity is much stronger than clinical actionability: diagnosis can be made molecularly, but prognosis and treatment remain based on six cases and general DEE practice. The most defensible knowledge-base entry should therefore preserve exact denominators, label mechanistic assignments as human-genetic plus model-supported, and mark epidemiology, QoL, long-term survival, biomarkers, genotype–phenotype correlation, and precision treatment as unknown. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1, neuray2020earlyinfantileonsetepilepsy pages 6-6, neuray2020earlyinfantileonsetepilepsy pages 1-1)

Principal reference: Neuray C, Maroofian R, Scala M, et al. Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants. Brain. Published online 10 July 2020;143(8):2388–2397. PMID: 32282878. DOI: https://doi.org/10.1093/brain/awaa178. (neuray2020earlyinfantileonsetepilepsy pages 3-3, neuray2020earlyinfantileonsetepilepsy pages 1-1)

References

  1. (neuray2020earlyinfantileonsetepilepsy pages 3-3): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  2. (neuray2020earlyinfantileonsetepilepsy pages 1-1): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  3. (OpenTargets Search: developmental and epileptic encephalopathy 89-GAD1): Open Targets Query (developmental and epileptic encephalopathy 89-GAD1, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  4. (neuray2020earlyinfantileonsetepilepsy pages 1-2): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  5. (neuray2020earlyinfantileonsetepilepsy pages 6-6): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  6. (neuray2020earlyinfantileonsetepilepsy pages 5-6): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  7. (neuray2020earlyinfantileonsetepilepsy pages 6-7): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  8. (neuray2020earlyinfantileonsetepilepsy pages 4-5): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

  9. (neuray2020earlyinfantileonsetepilepsy pages 8-9): Caroline Neuray, Reza Maroofian, Marcello Scala, Tipu Sultan, Gurpur S Pai, Majid Mojarrad, Heba El Khashab, Leigh deHoll, Wyatt Yue, Hessa S Alsaif, Maria N Zanetti, Oscar Bello, Richard Person, Atieh Eslahi, Zaynab Khazaei, Masoumeh H Feizabadi, Stephanie Efthymiou, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Bru Cormand, Belen Pérez-Dueñas, Gabriella Di Rosa, Jatinder S Goraya, Tipu Sultan, Jun Mine, Daniela Avdjieva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Marfa, Pierangelo Veggiotti, Michel D Ferrari, Alberto Verrotti, Giangluigi Marseglia, Salvatore Savasta, Mayte García-Silva, Alfons Macaya Ruiz, Barbara Garavaglia, Eugenia Borgione, Simona Portaro, Benigno Monteagudo Sanchez, Richard Boles, Savvas Papacostas, Michail Vikelis, Eleni Zamba Papanicolaou, Efthymios Dardiotis, Shazia Maqbool, Shahnaz Ibrahim, Salman Kirmani, Nuzhat Noureen Rana, Osama Atawneh, George Koutsis, Marianthi Breza, Salvatore Mangano, Carmela Scuderi, Eugenia Borgione, Giovanna Morello, Tanya Stojkovic, Massimi Zollo, Gali Heimer, Yves A Dauvilliers, Pasquale Striano, Issam Al-Khawaja, Fuad Al-Mutairi, Hamed Sherifa, Hala T El-Bassyouni, Doaa R Soliman, Selahattin Tekes, Leyla Ozer, Volkan Baltaci, Suliman Khan, Christian Beetz, Khalda S Amr, Vincenzo Salpietro, Yalda Jamshidi, Fowzan S Alkuraya, and Henry Houlden. Early-infantile onset epilepsy and developmental delay caused by bi-allelic gad1 variants. Brain, 143:2388-2397, Jul 2020. URL: https://doi.org/10.1093/brain/awaa178, doi:10.1093/brain/awaa178. This article has 56 citations and is from a highest quality peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 2
Resolved 2
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 2
On topic 2
Off topic 0

All extracted references resolved successfully.